MANAGEMENT OF DEMENTIA
(THIRD EDITION)
STATEMENT OF INTENT

These clinical practice guidelines (CPG) are meant to be guides for clinical practice, based on the best available evidence at the time of development. Adherence to these guidelines may not necessarily guarantee the best outcome in every case. Every healthcare provider is responsible for the management of his/her unique patient based on the clinical picture presented by the patient and the management options available locally.

UPDATING THE CPG

These guidelines were issued in 2021 and will be reviewed in a minimum period of four years (2025) or sooner if new evidence becomes available. When it is due for updating, the Chairperson of the CPG or National Advisor of the related specialty will be informed about it. A discussion will be done on the need for a revision including the scope of the revised CPG. A multidisciplinary team will be formed, and the latest systematic review methodology used by MaHTAS will be employed.

Every care is taken to ensure that this publication is correct in every detail at the time of publication. However, in the event of errors or omissions, corrections will be published in the web version of this document, which will be the definitive version at all time. This version can be found on the websites mentioned above.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Levels of Evidence and Formulation of Recommendation</td>
<td>i</td>
</tr>
<tr>
<td></td>
<td>Key Recommendations</td>
<td>ii</td>
</tr>
<tr>
<td></td>
<td>Guidelines Development and Objectives</td>
<td>iv</td>
</tr>
<tr>
<td></td>
<td>Development Group</td>
<td>vi</td>
</tr>
<tr>
<td></td>
<td>Review Committee</td>
<td>vii</td>
</tr>
<tr>
<td></td>
<td>External Reviewers</td>
<td>viii</td>
</tr>
<tr>
<td></td>
<td>Algorithm 1. Early Detection of Dementia</td>
<td>ix</td>
</tr>
<tr>
<td></td>
<td>Algorithm 2. Diagnosis of Dementia</td>
<td>x</td>
</tr>
<tr>
<td></td>
<td>Algorithm 3. Treatment of Dementia</td>
<td>xi</td>
</tr>
<tr>
<td>1.</td>
<td>INTRODUCTION</td>
<td>1</td>
</tr>
<tr>
<td>2.</td>
<td>RISK FACTORS AND RISK REDUCTION STRATEGIES</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2.1 Risk Factors</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2.2 Risk Reduction Strategies</td>
<td>4</td>
</tr>
<tr>
<td>3.</td>
<td>ASSESSMENT AND DIAGNOSIS</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>3.1 Assessment</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>3.1.1 Clinical Assessment</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>3.1.2 Imaging and Biomarkers</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>3.2 Diagnostic Criteria</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>3.3 Stages</td>
<td>10</td>
</tr>
<tr>
<td>4.</td>
<td>TREATMENT</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>4.1 Non-pharmacological Interventions</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>4.2 Pharmacological Interventions</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>4.2.1 Alzheimer’s Disease</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>4.2.2 Vascular Dementia</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>4.2.3 Lewy Body Disease (Dementia with Lewy Body/Parkinson’s Disease</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>4.2.4 Frontotemporal Dementia</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>4.2.5 Behavioural and Psychological Symptoms</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>4.2.6 Anticholinergic Concerns</td>
<td>21</td>
</tr>
<tr>
<td>5.</td>
<td>TRADITIONAL AND COMPLEMENTARY MEDICATION</td>
<td>22</td>
</tr>
<tr>
<td>6.</td>
<td>MILD COGNITIVE IMPAIRMENT</td>
<td>22</td>
</tr>
<tr>
<td>7.</td>
<td>SPECIAL POPULATION</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>7.1 Acquired Brain Injury</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>7.2 Alcohol-related Dementia</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>7.3 HIV-Associated Neurocognitive Disorders</td>
<td>24</td>
</tr>
<tr>
<td>8.</td>
<td>CAREGIVER SUPPORT</td>
<td>25</td>
</tr>
<tr>
<td>9.</td>
<td>LEGAL AND ETHICAL ISSUES</td>
<td>26</td>
</tr>
<tr>
<td>10.</td>
<td>PALLIATIVE AND END-OF-LIFE CARE</td>
<td>28</td>
</tr>
<tr>
<td>11.</td>
<td>REFERRAL</td>
<td>30</td>
</tr>
<tr>
<td>12.</td>
<td>IMPLEMENTING THE GUIDELINES</td>
<td>31</td>
</tr>
<tr>
<td>No.</td>
<td>Title</td>
<td>Page</td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td></td>
<td>12.1 Facilitating and Limiting Factors</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>12.2 Potential Resource Implications</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>REFERENCES</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>Appendix 1. Example of Search Strategy</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Appendix 2. Clinical Questions</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Appendix 3. 10 Warning Signs of Dementia</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Appendix 4. Initial Assessment Tools</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>Appendix 5. Diagnostic and Statistical Manual of Mental Disorder</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>Fifth Edition (DSM-5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Related Health Problems, 10th Revision (ICD-10)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Appendix 7. a. The Global Deterioration Scale for Assessment of</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td>Primary Degenerative Dementia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. Functional Assessment Staging (FAST)</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>Appendix 8. Medications Used for the Treatment of Dementia</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>Appendix 9. Anticholinergic Burden Scores</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>Appendix 10. Suggested Guide to Review and Deprescribe</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>(Potentially Inappropriate Prescription/Psychotropic) in Dementia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Appendix 11. Important Points for Caregiver of People with Dementia</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Appendix 12. Useful Resources</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td>Appendix 13. Advance Care Planning</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>List of Abbreviations</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>Acknowledgement</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>Disclosure Statement</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>Source of Funding</td>
<td>67</td>
</tr>
</tbody>
</table>
FORMULATION OF RECOMMENDATION

In line with the current development in CPG methodology, the CPG Unit of MaHTAS is in the process of adapting Grading Recommendations, Assessment, Development and Evaluation (GRADE) in its work process. The quality of each retrieved evidence and its effect size are carefully assessed and reviewed by the CPG Development Group. In formulating the recommendations, overall balances of the following aspects are considered in determining the strength of the recommendations:

- overall quality of evidence
- balance of benefits versus harms
- values and preferences
- resource implications
- equity, feasibility and acceptability

Sources:

- US / CANADIAN PREVENTIVE SERVICES TASK FORCE 2001

**LEVELS OF EVIDENCE**

<table>
<thead>
<tr>
<th>Level</th>
<th>Study design</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence from at least one properly randomised controlled trial</td>
</tr>
<tr>
<td>II-1</td>
<td>Evidence obtained from well-designed controlled trials without randomisation</td>
</tr>
<tr>
<td>II-2</td>
<td>Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one centre or group</td>
</tr>
<tr>
<td>II-3</td>
<td>Evidence from multiple time series with or without intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence</td>
</tr>
<tr>
<td>III</td>
<td>Opinions of respected authorities based on clinical experience; descriptive studies and case reports; or reports of expert committees</td>
</tr>
</tbody>
</table>
KEY RECOMMENDATIONS

The following recommendations are highlighted by the CPG Development Group as the key recommendations that answer the main questions addressed in the CPG and should be prioritised for implementation.

a. Risk Reduction

- Risk reduction strategies should be advocated to reduce the risk of developing cognitive decline and/or dementia. These include:
  - physical activity
  - tobacco cessation
  - interventions for alcohol use disorders
  - management of hypertension
  - management of diabetes

b. Assessment and Diagnosis

- The diagnosis of dementia should be based on detailed history and physical examination, and supported by cognitive, functional and behavioural evaluation.
- Structural neuroimaging (computed tomography or magnetic resonance imaging) should be done in evaluation of dementia to exclude reversible causes of cognitive decline and other intracranial pathology.
- Electroencephalogram should be considered in rapidly progressive cognitive decline and atypical features of dementia.
- Diagnosis of dementia should be made based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) or the International Classification of Diseases, Tenth Revision (ICD-10).

c. Non-Pharmacological Treatment

- To improve cognitive function in mild to moderate dementia, cognitive stimulation therapy and physical activity should be offered.
- In people with dementia having behavioural and psychological symptoms:
  - explore and address possible clinical or environmental causes/triggering factors
  - offer psychosocial and environmental interventions as initial and ongoing treatment:
    - psychological intervention for depressive symptoms and/or anxiety
    - personalised and tailored activities for agitation and aggression

d. Pharmacological Treatment

- Donepezil should be offered in Alzheimer’s Disease (AD) of all severity.
  - Rivastigmine is an option in mild to moderate AD.
- Memantine may be considered in moderate to severe AD as monotherapy or in combination with acetylcholinesterase inhibitors (AChEI).
- AChEI or memantine may be considered in vascular dementia.
- Rivastigmine or donepezil may be considered for dementia with Lewy body and Parkinson’s disease dementia.
- Antipsychotics may be considered for behavioural and psychological symptoms in people with dementia (PWD) where there is a risk of harming themselves or others.
- Antidepressants:
e. Caregiver Support

- Caregivers should be actively involved and supported in the management of dementia.
  - This includes assessment of the burden of caregivers.

f. Legal and Ethical Issues

- If there is any doubt regarding people with dementia (PWD)’s decision-making capacity, a formal assessment of decision-making capacity should be carried out.
- A doctor should comply with a patient’s unequivocal written directive to refuse a particular treatment if that decision was made while the patient had mental capacity.
- PWD (particularly moderate to severe) should be assessed for their driving ability if they still wish to drive.


g. Palliative and End-Of-Life Care

- Physical restraints should be avoided in dementia.
- Advance care planning should be considered in the management of dementia once the diagnosis is established.

h. Referral

- All patients with suspected dementia should be referred to a geriatric psychiatrist/psychiatrist, geriatrician or neurologist for assessment, diagnosis and management.
GUIDELINES DEVELOPMENT AND OBJECTIVES

GUIDELINES DEVELOPMENT

The members of the Development Group (DG) for these Clinical Practice Guidelines (CPG) were from the Ministry of Health (MoH) and Ministry of Higher Education. There was active involvement of a multidisciplinary Review Committee (RC) during the process of the CPG development.

A systematic literature search was carried out using the following electronic databases: mainly Medline via Ovid and Cochrane Database of Systemic Reviews and others e.g. PubMed and Guidelines International Network (refer to Appendix 1 for Example of Search Strategy). The search was limited to literature published on humans, "all adults (19 plus years)", publication from year "2009 to Current" and English language. In addition, the reference lists of all retrieved literature and guidelines were searched and, experts in the field contacted to identify relevant studies. All searches were conducted from 19 Nov 2018 to 26 Feb 2019. Literature searches were repeated for all clinical questions at the end of the CPG development process allowing any relevant papers published before 31 January 2021 to be included. Future CPG updates will consider evidence published after this cut-off date. The details of the search strategy can be obtained upon request from the CPG Secretariat.

References were also made to other CPGs on Dementia e.g.:

- Dementia: assessment, management and support for people living with dementia and their carers [National Institute for Health and Care Excellence (NICE), 2018]
- Clinical Practice Guidelines and Principles of Care for People with Dementia [National Health and Medical Research Council (NHMRC), 2016]
- Risk Reduction of Cognitive Decline and Dementia WHO Guidelines [World Health Organization (WHO), 2019]

These CPGs were evaluated using the Appraisal of Guidelines for Research and Evaluation (AGREE) II prior to them being used as references.

A total of 14 clinical questions (CQ) were developed under different sections. Members of the DG were assigned individual questions within these sections (refer to Appendix 2 for Clinical Questions). The DG members met 26 times throughout the development of these guidelines. All literature retrieved were appraised by at least two DG members using Critical Appraisal Skill Programme checklist, presented in evidence tables and further discussed in each DG meetings. All statements and recommendations formulated after that were agreed upon by both the DG and RC. Where evidence was insufficient, the recommendations were made by consensus of the DG and RC. This CPG is based largely on the findings of systematic reviews, meta-analyses and clinical trials, with local practices taken into consideration.

The literature used in these guidelines were graded using the US/Canadian Preventive Services Task Force Level of Evidence (2001), while the grading of recommendation was done using the principles of GRADE (refer to the preceding page). The writing of the CPG follows strictly the requirement of AGREE II.

On completion, the draft of the CPG was reviewed by external reviewers. It was also posted on the MoH Malaysia official website for feedback from any interested parties. The draft was finally presented to the Technical Advisory Committee for CPG, and the HTA and CPG Council MoH Malaysia for review and approval. Details on the CPG development methodology by MaHTAS can be obtained from Manual on Development and Implementation of Evidence-based Clinical Practice Guidelines published in 2015 (available at http://www.moh.gov.my/moh/resources/CPG_MANUAL_MAHTAS.pdf?mid=634).
OBJECTIVES

The objectives of the CPG are to provide evidence-based recommendations on the management of dementia in the following aspects:
   a. risk factors
   b. assessment and diagnosis
   c. treatment
   d. referral and follow-up

CLINICAL QUESTIONS

Refer to Appendix 2.

TARGET POPULATION

1. Inclusion Criteria
   Adults with:
   - dementia
   - mild cognitive impairment

2. Exclusion Criteria
   Adults with:
   - learning disabilities who develop dementia

TARGET GROUP/USERS

This document is intended to guide those involved in the management of dementia at any healthcare level including:
   i. doctors
   ii. allied health professionals
   iii. trainees and medical students
   iv. patients and their caregivers/advocates
   v. professional organisations

HEALTHCARE SETTINGS

Primary, secondary and tertiary care settings
DEVELOPMENT GROUP

Chairperson
Dr. Chan Yee Fai
Consultant Geriatric Psychiatrist
Hospital Kuala Lumpur, Kuala Lumpur

Members (in alphabetical order)

Dr. Ian Lloyd Anthony
Consultant Forensic Psychiatrist
Hospital Bahagia Ulu Kinta, Perak

Mr. Rajesweran Ramalingam
Pharmacist
Hospital Kuala Lumpur, Kuala Lumpur

Dr. Hor Jyh Yung
Consultant Neurologist
Hospital Pulau Pinang, Pulau Pinang

Ms. Rosita Abd Rahman
Occupational Therapist
Hospital Tuanku Ja’afar, Negeri Sembilan

Dr. Mohd Aminuddin Mohd Yusof
Public Health Physician & Head of CPG Unit
MaHTAS, Ministry of Health, Putrajaya

Dr. Suhaila Mohamad Zahir
Consultant Geriatric Psychiatrist
Hospital Tuanku Jaafar, Negeri Sembilan

Dr. Noor Ayuni Bazura Muhamad
Senior Principal Assistant Director
MaHTAS, Ministry of Health, Putrajaya

Dr. Teh Hoon Lang
Consultant Geriatrician
Hospital Sultanah Bahiyah, Kedah

Dr. Nor ‘izzati Saedon
Consultant Geriatrician
Pusat Perubatan Universiti Malaya
Kuala Lumpur

Dr. Valarmathi Masilamani
Family Medicine Specialist
Klinik Kesihatan Batu, Kuala Lumpur

Dr. Kenny Ong Kheng Yee
Consultant Neuropsychiatrist
Hospital Kuala Lumpur, Kuala Lumpur

Dr. Zaleha Jusoh
Family Medicine Specialist
Klinik Kesihatan Marang, Terengganu
REVIEW COMMITTEE

The draft guidelines were reviewed by a panel of experts. They were asked to comment primarily on the comprehensiveness and accuracy of the interpretation of evidence supporting the recommendations in the guidelines.

Chairperson
Dr. Hjh. Salina Abdul Aziz
Psychiatry Head of Service & Senior Consultant Psychiatrist
Hospital Kuala Lumpur, Kuala Lumpur

Members
- Dr. Izzuna Mudla Mohamed Ghazali
  Deputy Director & Public Health Physician
  MaHTAS, Ministry of Health, Putrajaya
- Dr. Santhi Datuk Puvanarajah
  Head of Neurology Department & Senior Consultant Neurologist
  Hospital Kuala Lumpur, Kuala Lumpur
- Associate Prof. Dr. Ng Chong Guan
  Consultant Psychiatrist
  Pusat Perubatan Universiti Malaya
  Kuala Lumpur
- Prof. Dr. Shahrul Bahyah Kamaruzzaman
  Senior Lecturer & Consultant Geriatrician
  Pusat Perubatan Universiti Malaya
  Kuala Lumpur
- Mr. Thillainathan Krishnan
  Occupational Therapist
  Family Health Development Division
  Ministry of Health, Putrajaya
- Dr. Phillip Poi Jon Hua
  Senior Consultant Geriatrician
  Sunway Medical Centre, Selangor
- Dr. Yau Weng Keong
  Head of Medical Department & Senior Consultant Geriatrician
  Hospital Kuala Lumpur, Kuala Lumpur
- Ms. Rosmaliah Alias
  Pharmacist
  Hospital Kuala Lumpur, Kuala Lumpur
- Datuk Dr. Yim Khai Kee
  Patient Advocate
  Alzheimer’s Disease Foundation Malaysia
- Dr. Ruziaton Hasim
  Consultant Family Physician Specialist
  Klinik Kesihatan Pandamaran, Selangor
EXTERNAL REVIEWERS (in alphabetical order)

The following external reviewers provided feedback on the draft:

Dr. Alan Pok Wen Kin  
Consultant Geriatrician  
Hospital Kuala Lumpur, Kuala Lumpur

Dr. Noraliza Noordin Merican  
Public Health Physician  
Elderly Health Sector, Family Health Section, Family Health Development Division, Ministry of Health, Putrajaya

Professor Dr. Andrew CK Law  
Vice Dean (International Student Services) & Head, Department of Psychiatry  
Royal College of Surgeons in Ireland & University College Dublin (Malaysia Campus), Pulau Pinang

Dr. Soraya Kunanayagam  
Consultant Geriatrician  
Gleneagles Hospital, Kuala Lumpur

Dr. Emma Fazilah Zulkifli  
Family Physician Specialist  
Klinik Famili Emma  
Subang Jaya, Selangor

Dr. Suraya Yusoff  
Consultant Geriatric Psychiatrist  
Johor

Professor Dr. Hj. Ismail Drahman  
Senior Consultant Geriatric Psychiatrist  
Hospital Sentosa, Sarawak

YTM Dato' Dr. Tunku Muzafar Shah Tunku Jaafar Laksmana  
Consultant Geriatrician  
Hospital Selayang, Selangor

Dr. Jeffrey Kirwan  
Consultant Old Age Psychiatrist  
Eastern Health, Melbourne, Australia

Professor Dr. Wendy Burn  
Consultant in Old Age Psychiatry  
Leeds and York Partnership NHS Foundation Trust, United Kingdom

Associate Prof. Dr. Lim Wee Shiong  
Senior Consultant Geriatrician  
Institute of Geriatrics and Active Aging  
Tan Tock Seng Hospital, Singapore

Dr. Wong Ping Foo  
Family Medicine Specialist  
Klinik Kesihatan Cheras Baru  
Kuala Lumpur

Mahmud Abu Bakar  
Patient Advocate  
Kuala Lumpur

Associate Prof. Dr. Zainol Akbar Zainal  
Clinical Pharmacist  
University of Cyberjaya, Selangor

Dr. Mark Tan Kiak Min  
Coordinator, Clinical Ethics Consultation Service, Hospital UiTM & Lecturer  
Universiti Teknologi Mara, Selangor

Dr. Zanariah Mat Saher  
Consultant Geriatric Psychiatrist  
Hospital Kuala Lumpur, Kuala Lumpur

Dato' Dr. Md. Hanip Rafia  
Senior Consultant Neurologist  
Kuala Lumpur
ALGORITHM 1: EARLY DETECTION OF DEMENTIA

Presence of symptoms suggestive of dementia (including subjective memory complaint, changes in activity of daily living and/or caregivers concerns), clinician suspicion and patients at increased risk of dementia

Perform clinical assessment:
- History from patients and/or caregivers
- Examination
  - Physical including cardiovascular and neurological systems
  - Mental state and cognition (e.g. mini-Cog/AMTS/MMSE)

Abnormalities detected on clinical assessment

Perform laboratory tests*

Any abnormalities present

Findings meet criteria for dementia

Symptoms remain

Patient is cognitively impaired but not demented

Refer to specialist services/memory clinic

Consider referral to a specialist and/or reassess in six months

Provide reassurance or referral as appropriate

Treat and reassess

Provide reassurance

*Refer to Chapter 3 on Diagnosis and Assessment

AMTS = Abbreviated Mental Test Score
MMSE = Mini Mental State Examination
ALGORITHM 2: DIAGNOSIS OF DEMENTIA

Referral on possible diagnosis of dementia

Perform clinical assessment:
- history from patients and/or caregivers
- examination
  - physical
  - cognition (e.g. MMSE, MoCA)
  - mental state (e.g. CSDD, NPI)
  - function (e.g. IADL/ADL)
  - others - caregivers burden (e.g. ZBI)

Patient is cognitively impaired

YES

Consider other diagnosis

NO

Laboratory tests for dementia screening to exclude potentially reversible causes (full blood count, biochemistry tests, thyroid function test, serum vitamin B12 and folate levels, VDRL and HIV tests)

Dementia or mild cognitive impairment

YES

Perform MRI/CT brain
- EEG if indicated

DEMENTIA

NO

MCI

Reassess after 6 months

YES

Determine type of dementia

Alzheimer’s disease
Vascular Dementia
Dementia with Lewy Body/Parkinson’s Disease Dementia
Fronto-temporal Dementia
Other types of dementia
- Mixed dementia
- Related to medical conditions
- HIV/TBI/alcohol-related dementia

MMSE = Mini Mental State Examination
MoCA = Montreal Cognitive Assessment
CSDD = Cornell Scale for Depression in Dementia
NPI = Neuropsychiatric Inventory
IADL = Instrumental Activity of Daily Living
ZBI = Zarit Burden Interview
VDRL = Venereal Disease Research Laboratory test
HIV = Human Immunodeficiency Virus
MRI = Magnetic Resonance Imaging
CT = Computed Tomography
EEG = Electroencephalogram
TBI = Traumatic Brain Injury
ALGORITHM 3: TREATMENT OF DEMENTIA

DEMENTIA

Non-pharmacological intervention

Psychosocial Intervention (tailored to individual’s needs)

Multidisciplinary team Involvement (multicomponent intervention for patients and care givers)

Maintenance of cognitive function and encouragement of independence

Improvement of quality of life

Pharmacological Intervention

Alzheimer's disease

Treat vascular risk factors

Mild

Moderate to severe

Consider AChEI or memantine

AChEi

Consider rivastigmine or donepezil

Donepezil and/or memantine

Dementia with Lewy Body/Parkinson's Disease Dementia

Frontotemporal Dementia

Vascular dementia

Behavioural and Psychological Symptoms of Dementia

• Agitation
• Aggression
• Psychosis

• Depression
• Anxiety

Co-morbid emotional disorders

• Assess and address clinical or environmental causes
• Offer psychosocial and environmental intervention
• Consider antipsychotics or antidepressants

• Assess and address clinical or environmental causes
• Offer psychosocial and environmental intervention
• Consider antidepressant in pre-existing condition

AChEI = acetylcholinesterase inhibitors
1. INTRODUCTION

Dementia is a syndrome in which cognitive function (i.e., ability to process thought) deteriorates progressively. It is not part of a normal ageing process. It affects memory, thinking, orientation, calculation, learning capacity, language, judgement, emotional control, social behaviour, or motivation (refer to Appendix 3 on 10 Warning Signs of Dementia). However, consciousness is not affected. Dementia can lead to disability and dependency among people with dementia (PWD). It is commonly associated with behavioural and psychological symptoms which can lead to increased dependency on caregivers and subsequent nursing home admission. The lack of awareness and understanding of dementia can lead to stigmatisation and delay in diagnosis and care. The physical, psychological, social and economic impact of dementia on caregivers, family and society is tremendous and often overlooked.

There are estimated 50 million PWD worldwide and 60% of them live in low- or middle-income countries. There are nearly 10 million new cases every year. According to Alzheimer’s disease International, the estimated number of PWD in Malaysia was 123,000 in 2015. This number was projected to be 261,000 by 2030 and further increase to 590,000 by 2050. Based on the Malaysian National Health and Morbidity Survey 2018: Elderly Health, the overall prevalence of probable dementia was 8.5% (95% CI 6.97 to 10.22).

Alzheimer’s disease (AD) is the commonest type of dementia (60 - 70%), followed by vascular dementia (VaD), mixed dementia, frontotemporal dementia (FTD), Dementia with Lewy bodies (DLB), Parkinson’s disease dementia (PDD) and others. People with AD often present initially with gradual episodic memory impairment. However, in early-onset AD (less than 65 years old), patients may present with behavioural (frontal), visual (posterior cortical atrophy) or language (logopenic) variants with relatively well-preserved memory until the later stages of the disease. VaD is associated with cardiovascular risk factors, and often present with impaired executive function, slowed processing speed and memory retrieval difficulties. Mixed dementia is a combination of two or more dementia types, most frequently AD with vascular pathology. In cases of behavioural variant frontotemporal dementia, the early manifestations tend to be changes in the personality with executive dysfunction prior to memory issues. People with DLB often experience fluctuating cognitive decline with prominent visual hallucinations and spontaneous motor parkinsonism. Dementia occurs at least a year after the onset of motor symptoms in people with PDD.

As Malaysia is moving towards an ageing nation, the country must prepare itself to address health issues pertaining to the older people e.g. non-communicable diseases (NCDs) including dementia. The second edition of clinical practice guidelines (CPG) on management of dementia was published in 2009. Since then, diagnostic criteria on dementia have been revised and become more comprehensive. There have been minor advancements in the treatment of PWD. These are addressed in the new edition of the CPG. Apart from that, new sections on risk reduction strategies and special populations are added. This third edition aims to update on the management of dementia and eventually improve the quality of care for PWD.

2. RISK FACTORS AND RISK REDUCTION STRATEGIES

2.1 Risk Factors

Dementia is caused by a combination of genetic and environmental factors. Risk factors for dementia can be divided into modifiable and non-modifiable risk.
Non-modifiable risk factors are:
- Advancing age: age ≥ 65 years is a risk factor for any dementia\(^{\text{MoH, 2009}}\)
- Sex: Female has higher risk of dementia especially in AD\(^{\text{MoH, 2009}}\)
- Genetic:
  - Early-onset AD accounts for 6 - 7% of all AD cases. Of this group, only 13% exhibit autosomal dominant transmission. Three causative gene mutations have been identified; amyloid β-protein precursor on chromosome 21, presenilin 1 on chromosome 14 and presenilin 2 on chromosome 1.\(^{\text{MoH, 2009}}\)
  - Late-onset AD (age of >65 years old) is considered to be multifactorial but involves a strong genetic predisposition. \(^{\text{Van Cauwenberge C et al., 2015, level III}}\) The genetic component itself is complex and heterogeneous.\(^{\text{MoH, 2009}}\)
  - The presence of the ε4 variant of the APOE gene (APOE4) may contribute to the development of late-onset AD and sporadic early-onset AD. However, presence of APOE ε4 itself is neither necessary nor sufficient to cause the disease. The APOE ε2 allele is thought to have a protective effect. Large-scale genome-wide association studies have identified at least 20 loci associated with disease risk. None of these risk loci has an effect comparable to APOE ε4, with OR ranging from 1.1 to 2.0. \(^{\text{Van Cauwenberge C et al., 2015, level III}}\)

Modifiable risk factors can be divided into:

a. **Cardiovascular**

Major cardiovascular risk factors e.g. hypertension, diabetes mellitus, hyperlipidaemia, obesity and smoking are independent risk factors for the development of atherosclerosis VaD.
- Hypertension occurring at mid-life (40 to 60 years old) is a risk factor for dementia and should be appropriately treated.\(^{\text{MoH, 2009}}\) A systematic review showed that treatment of elderly patients with hypertension improved cognitive function especially for those on angiotensin II receptor blockers (ARB).\(^{\text{Stuchec M et al., 2017, level I}}\)
- Diabetes mellitus (DM) is a modifiable risk factor for the development of dementia and should be appropriately treated.\(^{\text{MoH, 2009}}\) A meta-analysis showed DM was a risk factor for all types of dementia (RR=1.73, 95% CI 1.65 to 1.82), whereas it was also a risk for AD (RR=1.56, 95% CI 1.41 to 1.73) and VaD (RR=2.27, 95% CI 1.94 to 2.66). However, there were methodological issues noted in the primary papers.\(^{\text{Gudala K et al., 2013, level II-2}}\)
- High total serum cholesterol (TC) is a risk factor for developing late-life dementia: \(^{\text{Anstey KJ et al., 2017, level II-2}}\)
  - High TC in mid-life compared with non-high TC is associated with risk of late-life AD (RR=2.14, 95% CI 1.33 to 3.44).
  - High TC in late-life is not associated with any cognitive or dementia outcome in late-life (RR=1.02, 95% CI 0.88 to 1.87).
- In a meta-analysis, serum LDL-C level was higher in AD patients compared with healthy control (OR=2.55, 95% CI 1.25 to 5.22). The quality of primary papers was good although there was high heterogeneity and confounders were not fully explained.\(^{\text{Sáiz-Vazquez O et al., 2020, level II-2}}\)
- Obesity is a modifiable risk factor and maintenance of normal body mass index (BMI) is recommended.\(^{\text{MoH, 2009}}\) This is supported by two meta-analyses showing that:
  - mid-life (age 35 to 65 years) BMI ≥30 and BMI ≤18.5 were associated with late-life dementia with risk of 1.33 (95% CI 1.08 to 1.63) and 1.39 (95% CI 1.13 to 1.70) respectively\(^{\text{Albanese E et al., 2017, level II-2}}\)
  - obesity (BMI ≥30) in mid-life were associated with risk of developing AD (RR=2.04, 95% CI 1.59 to 2.62) and any dementia (RR=1.64, 95% CI 1.34 to 2.00) compared with normal BMI\(^{\text{Anstey KJ et al., 2011, level II-2}}\)

b. **Psychiatric illness**

Late-life depression is associated with a two-fold increased risk of dementia (RR=1.98, 95% CI 1.50 to 2.63) and AD (RR=2.04, 95% CI 1.40 to 2.98).\(^{\text{Cherbuin N et al., 2015, level II-2}}\)
c. Lifestyle

- Smoking
  Tobacco smoking is a risk factor for cognitive impairment and dementia.\(^\text{WHO, 2019}\)

- Excessive alcohol consumption
  Heavy (＞12 and ≤24 g/d) and very heavy (＞24 g/d) alcohol consumption is a risk factor for incident dementia with HR of 1.10 (95% CI 1.01 to 1.19) and 1.18 (95% CI 1.01 to 1.36) respectively.\(^\text{Handing EP et al., 2015, level II-2}\)

- Physical inactivity
  A meta-analysis showed that physical inactivity measured ＜10 years before dementia diagnosis was associated with increased incidence of all-cause dementia (HR=1.40, 95% CI 1.23 to 1.71) and AD (HR=1.36, 95% CI 1.12 to 1.65). When reverse causation was minimised by assessing physical activity ≥10 years before all-cause dementia and AD onset, no difference in dementia risk between physically active and inactive participants was found for the two outcomes.\(^\text{Kivimäki M, et al. 2019; level II-2}\)

  However, there was no standard definition of self-reported physical inactivity and quality assessment in the primary papers used in the meta-analysis.

- Social relationship
  A meta-analysis of 19 cohort studies showed that low social participation (RR=1.41, 95% CI 1.13 to 1.75), less frequent social contact (RR=1.57, 95% CI 1.32 to 1.85) and more loneliness (RR=1.58, 95% CI 1.19 to 2.09) were associated with incident dementia. However, there were variations in social relationship factor measurements, adjustment of potential confounders and substantial dropout in the primary studies.\(^\text{Kuiper JS et al., 2015, level II-2}\)

d. Environment

A systematic review showed different strengths of evidence on the association between environmental elements and dementia.\(^\text{Killin LOJ et al., 2016, level II-2}\)

- Strong evidence (reported association with dementia in the majority of published papers) was seen in nitrogen oxide, ozone and particulate matter in the air.
- Environmental tobacco smoke showed dose-response based on cumulative dose score (calculated as level years of exposure based on setting, level and duration of exposure) as shown below.

<table>
<thead>
<tr>
<th>Level years of exposure</th>
<th>aHR</th>
</tr>
</thead>
<tbody>
<tr>
<td>＞0 - 24</td>
<td>0.99, 95% CI 0.76 to 1.28</td>
</tr>
<tr>
<td>25 - 49</td>
<td>1.15, 95% CI 0.93 to 1.42</td>
</tr>
<tr>
<td>50 - 74</td>
<td>1.18, 95% CI 0.87 to 1.59</td>
</tr>
<tr>
<td>75 - 99</td>
<td>1.39, 95% CI 1.03 to 1.84</td>
</tr>
<tr>
<td>≥100</td>
<td>1.95, 95% CI 1.34 to 2.83</td>
</tr>
</tbody>
</table>

e. Others

The Lancet Commission (2020) found several risk factors associated with dementia e.g.:\(^\text{Livingston G et al., 2020, level III}\)

- lower early life education level (RR=1.6, 95% CI 1.3 to 2.0)
- mid-life hearing impairment (RR=1.9, 95% CI 1.4 to 2.7)
- mid-life traumatic brain injury (TBI) (RR=1.8, 95% CI 1.5 to 2.2)

f. Co-occurrence of modifiable risk factors

Exposure to additional modifiable risk factors of dementia should be kept to the minimum. A meta-analysis on dementia outcomes revealed a pooled RR for dementia of 1.20 (95% CI 1.04 to 1.39) for one risk factor, 1.65 (95% CI 1.40 to 1.94) for two risk factors and 2.21 (95% CI 1.78 to 2.73) for three or more compared with no risk factor.\(^\text{Peters R. et. al., 2019, level II-2}\)
2.2 Risk Reduction Strategies

WHO recommends strategies to reduce the risk of cognitive decline and/or dementia in adults with normal cognition which include: \(^{WHO, 2019}\)

- physical activity
- tobacco cessation
- interventions for alcohol use disorders
- management of hypertension
- management of diabetes

Other interventions that may be considered are: \(^{WHO; 2019; Livingston G et al., 2020, level III}\)

- weight management
- management of dyslipidaemia
- nutritional interventions
- social activities
- cognitive interventions
- management of depression
- management of hearing loss

Tobacco cessation

- Smoking of tobacco and tobacco products (cigarette, electronic cigarette/vape, shisha, pipe, cigar etc.) can lead to various non-communicable diseases (NCDs). Worldwide, more than eight million people die every year because of this habit.\(^{WHO Tobacco Fact Sheet, 2020}\)

- Hence, the decision to integrate smoking treatment with NCDs is important to reduce the prevalence of NCDs and their complications. This decision was made during the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) Steering Committee Meeting in December 2019 chaired by the Honourable Health Minister of Malaysia.

- The treatment for smoking should be initiated by the treating doctor based on the assessment and treatment of tobacco use disorder as in Table 1. Details on this can be found in the CPG on Treatment of Tobacco Use Disorder 2016, available at:


<table>
<thead>
<tr>
<th>ASSESSMENT AND TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Ask and document smoking status for all patients.</td>
</tr>
<tr>
<td>2. Provide brief advice on quit smoking at every visit to all smokers.</td>
</tr>
<tr>
<td>3. Assess level of nicotine addiction using Modified Fagerström Test for Cigarette Dependence Questionnaire (COMPULSORY) and verify smoking status using carbon monoxide breath analyser (IF AVAILABLE).</td>
</tr>
<tr>
<td>4. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated.</td>
</tr>
<tr>
<td>5. If selected, use nicotine replacement therapy (NRT) for at least eight to twelve weeks, whereas varenicline should be used for at least twelve weeks.</td>
</tr>
<tr>
<td>6. Combination therapy (e.g. two NRTs, a non-NRT, e.g. bupropion with an NRT) is better than monotherapy in smoking cessation treatment and may be most useful for those smokers at highest risk of relapse.</td>
</tr>
</tbody>
</table>
7. Use smoking cessation medications with caution in special populations (e.g. children and adolescents, pregnant, breastfeeding women, psychiatric and substance abuse disorder patients).

8. Arrange a minimum of six to eight face to face follow-up sessions for smoking cessation interventions in six months through counselling support team (health education officer, pharmacists or any officer trained for quit smoking services).

**Medication and Supplement**

In a Cochrane systematic review of 28 RCTs with low risk of bias, vitamins (folic acid, vitamin B6 and B12, antioxidant vitamins [vitamin A, C and E] and vitamin D) and mineral supplementation (zinc and copper) did not maintain cognitive function in cognitively healthy people in mid (<70 years old) and late life at 5 - 10 years follow-up.\[^{6}\] Rutjes AWS et al., 2018, level I

Another three Cochrane systematic review studying on the association of supplements and medication with dementia found:

- no benefits or harms from vitamin E supplements in dementia\[^{2}\] Farina N et al., 2017, level I
- no evidence to support the use of either aspirin or other NSAIDs for prevention of dementia\[^{7}\] Jordan F et al., 2020, level I
- statins given to people at risk of vascular disease did not prevent cognitive decline or dementia compared with placebo\[^{8}\] McGuinness B et al., 2016, level I

- There is insufficient evidence to support the use of medication (aspirin and statins), vitamins and supplements to prevent dementia.

**Recommendation 1**

- Risk reduction strategies should be advocated to reduce the risk of developing cognitive decline and/or dementia. These include:
  - physical activity
  - tobacco cessation
  - interventions for alcohol use disorders
  - management of hypertension
  - management of diabetes

**3. ASSESSMENT AND DIAGNOSIS**

The evaluation of dementia should be targeted at patients who present with memory complaints (by patients themselves and/or carer), have clinical suspicion of cognitive impairment or are at increased risk for dementia as well as elderly patients who have questionable mental capacity.\[^{SMOH, 2013}\] The evidence on routine screening for cognitive impairment among asymptomatic community-dwelling adults age 65 and older is insufficient to determine the balance of its benefits and harms.\[^{USPSTF, 2020}\]

Initial assessment may be performed using various cognitive assessment tools. If dementia is suspected on clinical assessment, laboratory tests for basic dementia screening should be performed that include full blood count, biochemistry tests (glucose, lipid, electrolytes, renal and liver function tests, and calcium level), thyroid function test and, serum vitamin B12 and folate levels, to exclude potentially reversible causes as shown in Table 2 and to identify risk factors for dementia. When the initial evaluation is suggestive of dementia, patients need to be referred to specialist services (e.g. geriatrics/psychiatry/neurology) for further assessment and confirmation of diagnosis. Refer to Algorithm 1 on Early Detection of Dementia.
### Table 2: Some dementia-mimicking conditions

<table>
<thead>
<tr>
<th>Conditions that can be excluded by laboratory tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypothyroidism</td>
</tr>
<tr>
<td>Vitamin B12 deficiency</td>
</tr>
<tr>
<td>Folate deficiency</td>
</tr>
<tr>
<td>Hypercalcaemia</td>
</tr>
<tr>
<td>Neurosyphilis</td>
</tr>
<tr>
<td>HIV-related dementia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conditions that can be excluded by imaging/EEG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal pressure hydrocephalus</td>
</tr>
<tr>
<td>Subdural haemorrhage</td>
</tr>
<tr>
<td>Brain tumour</td>
</tr>
<tr>
<td>Creutzfeldt-Jakob disease</td>
</tr>
<tr>
<td>Autoimmune/limbic encephalitis</td>
</tr>
</tbody>
</table>

- Laboratory tests for basic dementia screening are indicated to exclude dementia-mimicking conditions.

### 3.1 Assessment

#### 3.1.1 Clinical Assessment

A detailed history from patient and reliable informants, and a comprehensive physical examination are the basis of clinical evaluation for dementia. Clinical assessment should include cognitive domain and non-cognitive domain as well. During clinical assessment, clinicians should exclude delirium and other mental disorders before diagnosing dementia.

- **Cognitive domain**

There are many cognitive assessment tools available to support the diagnosis of dementia. It can be divided into informant-rated instruments and direct patient assessment instruments. Summary of the commonly used cognitive assessment tools are shown in **Table 3**.

### Table 3. Common cognitive assessment tools in clinical practice

<table>
<thead>
<tr>
<th>Cognitive assessment tools</th>
<th>Accuracy</th>
<th>Validation in local languages</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity (95% CI)</td>
<td>Specificity (95% CI)</td>
</tr>
<tr>
<td>Informant-rated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. AD8 Dementia Screening Interview&lt;sup&gt;Hendry K et al, 2019, level II-2&lt;/sup&gt;</td>
<td>Cut-off point of 2: 0.92 (0.86 - 0.96)</td>
<td>0.64 (0.39 - 0.82)</td>
</tr>
<tr>
<td></td>
<td>Cut-off point of 3: 0.91 (0.80 - 0.96)</td>
<td>0.76 (0.57 - 0.89)</td>
</tr>
<tr>
<td>2. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)&lt;sup&gt;Harrison JK et al., 2016, level III&lt;/sup&gt;</td>
<td>Cut-off point &gt;3.0 - 3.3:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range 0.75 - 0.86</td>
<td>Range 0.38 - 0.90</td>
</tr>
<tr>
<td>Direct patient assessment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Mini-Cog&lt;sup&gt;Tsoi KK et al., 2015, level I&lt;/sup&gt;</td>
<td>0.91 (0.80 - 0.96)</td>
<td>0.86 (0.74 - 0.93)</td>
</tr>
<tr>
<td>2. Abbreviated Mental Test Score (AMTS)&lt;sup&gt;Jackson TA et al., 2013, level III&lt;/sup&gt;</td>
<td>Cut-off point &lt;7: 0.81 (0.76 - 0.86)</td>
<td>0.84 (0.83–0.85)</td>
</tr>
</tbody>
</table>
A systematic review on Cognitive Assessment Tools in Asia showed that educational bias was present in 74% of the studies with wide range of sensitivity and specificity which may lead to over estimation of dementia prevalence. Hence, diagnosis of dementia should not be made based on cognitive assessment score solely. The assessment score can be used to support the diagnosis of dementia and to monitor the disease progress. The choice of cognitive assessment tool depends on the clinical setting and the experience of the clinician. Refer to Appendix 4 on Initial Assessment Tools in Dementia.

Further evaluation with detailed neuropsychological tests can be considered if the diagnosis of dementia is still doubtful after initial assessment or to determine the subtype of dementia.

- **Non-cognitive domain**

Two systematic reviews on the Neuropsychiatric Inventory (NPI) showed that:

- it was able to identify behavioural and psychological symptoms in persons with Alzheimer’s dementia
- the items on irritability, agitation, anxiety, apathy, sleep disturbances and delusion exerted the most impact on caregiver for PWD

The NPI and Behavioral Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD) were utilised:

- to assess the presence and severity of behavioural and psychological symptoms in PWD with proven good psychometric properties, sensitivity to pharmacological and non-pharmacological interventions, and applicability to various institutional, outpatient and community settings
- in particular, to identify delusions and hallucinations in PWD among the nursing home residents

A cut-off score ≤5 and ≤7 for Cornell Scale for Depression in Dementia (CSDD) and Montgomery-Asberg Depression Rating Scale (MADRS) respectively give a 100% sensitivity in the screening of depression in nursing home residents with dementia when the source of information is from the professional caregivers.
A systematic review on instrumental activities of daily living (IADL) showed that Disability Assessment for Dementia (DAD) and Bristol Activities of Daily Living Scale (Bristol ADL) had the best ratings among 12 questionnaires despite lack of psychometric properties.\textsuperscript{Sikkes SAM et al., 2008, level III}

In another systematic review on caregiver burden, the Zarit Burden Interview (ZBI, 22-item version) had strong psychometric properties [reliability (Cronbach's alpha ranging from 0.70 to 0.93) and validity] and had been used for caregivers in the care of PWD.\textsuperscript{Whalen KJ & Buchholz SW, 2009, level III}

**Recommendation 2**

- The diagnosis of dementia should be based on detailed history and physical examination, and supported by cognitive, functional and behavioural evaluation.

3.1.2 Imaging and Biomarkers

- **Structural neuroimaging**

Structural neuroimaging with computed tomography (CT) or magnetic resonance imaging (MRI) is usually offered in the assessment of people with suspected dementia to exclude reversible causes of cognitive decline and other cerebral pathologies, and to assist in subtype diagnosis.\textsuperscript{NICE 2018, Australian guideline 2016} The second edition of this CPG recommends structural neuroimaging e.g. CT and MRI brain to be done where available in the evaluation of dementia to exclude intracranial pathology.\textsuperscript{MoH, 2009}

Some conditions that mimic dementia can be detected and excluded by structural neuroimaging are listed in Table 2.

A narrative review of structural MRI on patients with AD revealed cerebral atrophy. The progression of atrophy follows Braak staging and is first observed at medial temporal lobe structures, including hippocampus and entorhinal cortex with a reduction of 26% and 40% respectively compared with controls. Other limbic structures including amygdala, olfactory bulb tract, cingulate gyrus, and thalamus are involved later. As the disease progresses, the atrophy spreads to cortical regions causing volume reduction.\textsuperscript{Chandra A et al., 2019, level III} Visual rating scales for medial temporal lobe may be useful to grade the degree of medial temporal atrophy on CT or MRI.\textsuperscript{Harper L et al., 2015, level III}

MRI is recommended if dementia subtype is uncertain and VaD is suspected. CT can be used if MRI is unavailable or contraindicated. It is readily available and better tolerated. However, VaD should not be diagnosed based solely on vascular lesion burden on imaging because the extent of vascular damage required to impair a person’s cognitive function is still unclear.\textsuperscript{NICE, 2018}

- **Functional neuroimaging**

NICE recommends further testing with functional neuroimaging should only be considered if it helps to diagnose a dementia subtype and change the patient’s subsequent management.\textsuperscript{NICE, 2018}

Fluorodeoxyglucose-positron emission tomography (FDG-PET) or perfusion single-photon emission CT (SPECT) can be considered if the dementia diagnosis is uncertain and AD or FTD is suspected. Iodine 123-radiolabeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (\textsuperscript{123}I-FP-CIT) SPECT or \textsuperscript{123}I-metaiodobenzylguanidine (\textsuperscript{123}I-MIBG) cardiac scintigraphy can be considered if the dementia diagnosis is uncertain and DLB is suspected.\textsuperscript{NICE, 2018} A Cochrane systematic review showed that dopamine transporter (DAT)
imaging is a promising test for diagnosing DLB, though the evidence was derived from only one small study. A normal DAT imaging may be an accurate means to exclude the diagnosis of DLB. McCleery J et al., 2015, level III.

Two Cochrane systematic reviews did not support routine use of FDG-PET and \(^{11}\)C-labeled Pittsburgh compound B-positron emission tomography (\(^{11}\)C-PIB-PET) scans for the early diagnosis of AD and other dementia subtypes in people with Mild Cognitive Impairment (MCI). Smallagic N et al., 2015, level III; Zhang S et al., 2014, level III. In fact, an Australian guideline recommends that SPECT should not be used to differentiate MCI from dementia. Australian guideline, 2016.

- **Electroencephalogram**
  Electroencephalogram (EEG) is not routinely used in the investigation of dementia. NICE 2018, Australian guideline 2016. It should be considered when there is rapidly progressive cognitive decline and atypical features of dementia e.g. CJD, autoimmune/limbic encephalitis.

  A systematic review of dementia subtypes showed that a normal EEG result rendered a diagnosis of DLB very unlikely. Non-specific slowing of background rhythm on EEG was seen in >90% of DLB cases as opposed to an estimated 10% of AD cases. Law ZK et al., 2020, level III.

- **Cerebrospinal fluid biomarkers**
  After clinical assessment and structural neuroimaging, if the diagnosis remains uncertain and AD is suspected, lumbar puncture may be considered to examine the cerebrospinal fluid (CSF) for total tau or total tau and phosphorylated-tau 181, and amyloid beta 1-42 or amyloid beta 1-42 and amyloid beta 1-40. NICE, 2018.

  In view of insufficient and heterogeneity of evidence, a Cochrane systematic review did not recommend the use of CSF tau and CSF tau/amyloid beta ratio to identify people with MCI who would clinically convert to AD later. Ritchie C et al., 2017, level I.

**Recommendation 3**

- Structural neuroimaging (computed tomography or magnetic resonance imaging) should be done in evaluation of dementia to exclude reversible causes of cognitive decline and other intracranial pathology.
- Functional neuroimaging may be considered if the diagnosis of dementia is uncertain.
- Electroencephalogram should be considered in rapidly progressive cognitive decline and atypical features of dementia.

### 3.2 Diagnostic Criteria

There are a few diagnostic criteria available for each subtypes of dementia, the majority are for clinical use and some are for research purpose (refer to Table 4). Major changes have been made to diagnostic criteria for dementia in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) published in 2013. Major neurocognitive disorder is used to replace dementia while mild neurocognitive disorder is introduced for MCI. It only requires decline in one or more of the cognitive domains, which is severe enough to interfere with daily activities, to diagnose major neurocognitive disorder. The latest edition of DSM-5 helps clinicians to diagnose different types of dementia more easily. Another diagnostic criteria that can be used in the diagnosis of dementia is the International Classification of Diseases, Tenth Revision (ICD-10). Refer to **Appendix 5 on DSM-5** and **Appendix 6 on ICD-10**.
Table 4. Diagnostic Criteria for Subtypes of Dementia

<table>
<thead>
<tr>
<th>Dementia Subtypes</th>
<th>Diagnostic Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer's Disease</td>
<td>• National Institute on Aging and Alzheimer's Association (NIA-AA)</td>
</tr>
<tr>
<td>Vascular Dementia</td>
<td>• National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN)</td>
</tr>
<tr>
<td></td>
<td>• Alzheimer's Disease Diagnostic and Treatment Centers (ADDTC)</td>
</tr>
<tr>
<td>Mixed Dementia</td>
<td>-</td>
</tr>
<tr>
<td>Parkinson's Disease Dementia (PDD)</td>
<td>• Movement Disorder Society (MDS) guidelines for diagnosis of PDD</td>
</tr>
<tr>
<td>Dementia of Lewy Body (DLB)</td>
<td>• Fourth consensus report of the DLB Consortium</td>
</tr>
<tr>
<td>Frontotemporal Dementia (FTD)</td>
<td>• International consensus criteria for behavioural variant FTD</td>
</tr>
</tbody>
</table>

**Recommendation 4**
- Diagnosis of dementia should be made based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) or the International Classification of Diseases, Tenth Revision (ICD-10)

Refer to Algorithm 2 on Diagnosis of Dementia.

### 3.3 Stages

The severity of dementia can be staged according to functional status as stated in DSM-5 as shown below.

<table>
<thead>
<tr>
<th>Severity</th>
<th>Functional status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>Difficulties with instrumental activities of daily living (e.g. housework, managing money).</td>
</tr>
<tr>
<td>Moderate</td>
<td>Difficulties with basic activities of daily living (e.g. feeding, dressing).</td>
</tr>
<tr>
<td>Severe</td>
<td>Fully dependent</td>
</tr>
</tbody>
</table>

In addition, severity of dementia can also be assessed using the Global Deterioration Scale for Assessment of Primary Degenerative Dementia and Functional Assessment Staging (FAST). FAST is especially useful for grading severity in more advanced stages of dementia (FAST stage 6 and 7). Refer to Appendix 7a and 7b for the mentioned scales.

### 4. Treatment

Specialists in the care of dementia (psychiatrists/geriatric-psychiatrists/neuropsychiatrists, neurologists/geriatricians and physicians or family medicine specialists with special interest training in geriatric care) should initiate treatment in PWD. Once treatment is initiated, PWD should be regularly reviewed to assess cognition, behavioural and psychological symptoms of dementia (BPSD), global functioning and potential side effects. Management of dementia can be divided into non-pharmacological and pharmacological approach. Non-pharmacological
interventions should be the mainstay of treatment in PWD throughout all stages of the condition.

- For those who require regular medication, the ‘3T’ approach is a good practice: MoH, 2009
  - treatments should have a specific target symptom
  - the starting dose should be low and then titrated upwards
  - treatments should be time limited

4.1 Non-pharmacological Interventions

Non-pharmacological interventions attempt to promote positive effects on cognition, quality of life, mood and, other behavioural and psychological symptoms of dementia. They have shown to have potential benefits in the management of dementia.

- Cognition and Quality of life

A meta-analysis showed that physical activity interventions improved cognitive function (SMD=0.42, 95% CI 0.23 to 0.62) compared with control in PWD. In terms of type of intervention, positive results were seen in combined exercise interventions (SMD=0.59, 95% CI 0.32 to 0.86) and aerobic-only exercise interventions (SMD=0.41, 95% CI 0.05 to 0.76) only. Both high and low frequency interventions were also effective, Groot C et al., 2016, level I

There are three major types of cognitive approaches:
  - cognitive stimulation - entails exposure to and engagement with activities and materials involving some degree of cognitive processing
  - cognitive training - a specific training exercise geared to specific cognitive functions and, includes practice and repetition which may be computer-assisted
  - cognitive rehabilitation - include working on personal goals, often using external cognitive aids and with some use of learning strategies

In two Cochrane systematic reviews on mild to moderate dementia:
  - moderate quality evidence showed that cognitive stimulation therapy given either through specific manual or general activities improved cognitive function (SMD=0.41, 95% CI 0.25 to 0.57); it can be carried out at patient’s own home, day care, outpatient or at residential setting by caregiver with minimal training, Woods B et al., 2012, level I
  - low to moderate quality evidence demonstrated that cognitive training was not associated with improvement in global measure of cognition (SMD=0.10, 95% CI -0.21 to 0.40), Bahar-Fuchs A et al., 2013, level I

NICE recommends group cognitive stimulation therapy to people with mild to moderate dementia. It also recommends cognitive rehabilitation or occupational therapy to support functional ability in the same group of PWD, NICE, 2018

In a Cochrane systematic review, reminiscence therapy (RT) showed no improvement in self-rated quality of life (QoL) compared with no treatment in PWD (SMD=0.11, 95% CI -0.12 to 0.33). The quality of evidence was moderate based on GRADE, Woods B et al., 2018, level I However, NICE recommends group RT to promote cognition, independence and well-being of PWD, NICE, 2018

In another systematic review on cognition and quality of life, spirituality and religious activities delayed cognitive decline and improve QoL of PWD, Agli O et al., 2014, level II-2
Recommendation 5
- To improve cognitive function in mild to moderate dementia, cognitive stimulation therapy and physical activity can be offered

- **Behaviour and Psychological symptoms**
Before starting non-pharmacological or pharmacological treatment for distress or BPSD in PWD, NICE recommends structured assessment exploring and addressing possible reasons for their distress including clinical or environmental causes e.g. pain, delirium or inappropriate care. Psychosocial and environmental interventions should be offered as initial and ongoing management, to reduce distress in PWD. NICE, 2018

Anxiety and depression are very common in PWD. Psychological interventions have been suggested as a potential treatment for this population.

In a Cochrane systematic review, psychological interventions, e.g. cognitive behavioural therapy (CBT) and, multifaceted and semi-tailored interventions (e.g. counselling sessions, education and outreach support to patients and carers) reduced depressive symptoms (SMD= -0.22, 95% CI 0.41 to -0.03) and clinician-rated anxiety (MD= -4.57, 95% CI 7.81 to -1.32) compared with treatment as usual in dementia. The primary papers were of low to moderate quality. Orgeta V et al., 2014, level I

PWD who are being cared in long-term care settings are often not involved in meaningful activities. Offering them activities may improve their quality of life and reduce challenging behaviour. Nevertheless, in a Cochrane systematic review, personally-tailored activities showed no significant reduction in challenging behaviour and improvement in self-rated QoL among PWD in long-term care setting. However, the evidence is of low quality. Mohler R et al., 2018, level I. On the other hand, NICE recommends to offer personalised activities in PWD with agitation or aggression to promote engagement, pleasure and interest. NICE, 2018

In a meta-analysis of three high-quality RCTs, multicomponent interventions for caregivers showed 33% less institutionalisation after 6 - 12 months (RR=0.67, 95% CI 0.49 to 0.92) compared with minimal support or usual care in mild to moderately severe AD. The intervention were long-term programmes comprised of education and support for caregivers plus other components e.g. respite care and support groups, tailored to the needs of PWD. Olazaran J et al., 2010, level I

Other non-pharmacological interventions on PWD addressed in systematic reviews/meta-analysis are shown in Table 5.

**Table 5: Other non-pharmacological interventions on PWD**

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Effectiveness</th>
<th>Quality of evidence</th>
</tr>
</thead>
</table>
| Music-based therapy vs usual care<sup>1</sup><sup>1</sup>van der Steen JT et al., 2018, level I | - Reduced depressive symptoms (SMD= -0.27, 95% CI -0.45 to -0.09)  
- Reduced overall behaviour problems (SMD= -0.23, 95% CI -0.46 to -0.01) | Moderate |
| Aromatherapy vs placebo<sup>2</sup>Forrester LT et al., 2014, level I | - Equivocal findings on agitation and behavioural symptoms | Very low (GRADE) |
| Massage and touch vs daily routine care or being accompanied<sup>3</sup>Wu J et al., 2017, level I | Improved:  
- behavioural problems (SMD= -0.39, 95% CI -0.53 to -0.25)  
- negative emotions (SMD= -0.60, 95% CI -1.14 to -0.06) | Low to moderate (GRADE) |
### Validation therapy vs usual care
Neal M et al., 2009, level I
- Insufficient evidence on behaviour and emotional state
  - Low

### Light therapy vs usual care
Forbes D et al., 2014, level I
- No effect on sleep, challenging behaviour or psychiatric symptoms
  - Moderate

### Simulated presence therapy vs usual care
Abraha I et al., 2017, level I
- Inconclusive efficacy on behavioural and psychological symptoms, and QoL
  - Very low (GRADE)

### Snoezelen vs control
Vilela VC et al., 2017, level I
- No effect on mood, behaviour, communication and cognition
  - Low

#### Recommendation 6
- In people with dementia having behavioural and psychological symptoms:
  - explore and address possible clinical or environmental causes/triggering factors
  - offer psychosocial and environmental interventions as initial and ongoing treatment:
    - psychological intervention for depressive symptoms and/or anxiety
    - personalised and tailored activities for agitation and aggression

Refer to **Algorithm 3** on **Treatment of Dementia**.

### 4.2 Pharmacological Interventions

No new drug has been licensed for the treatment of dementia since the previous edition of the CPG published in 2009.

The three acetylcholinesterase inhibitors (AChEI) (donepezil, galantamine and rivastigmine) as well as the N-methyl-D-aspartate (NMDA) receptor antagonist (memantine) are still the mainstay treatment in managing PWD.

AChEI works by augmenting the levels of acetylcholine in the brain to compensate for the losses of cholinergic function. Additionally, galantamine also modulates activity at nicotinic receptors.

Memantine is a voltage-dependent, moderate-affinity, uncompetitive NMDA receptor antagonist that inhibits the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.\(^{Bond M, 2012}\)

- Available pharmacological treatment for dementia is not curative; however they are aimed at managing symptoms (cognitive, non-cognitive and behavioural), improve independence and preserve function.\(^{NICE, 2018}\)

Currently under the MoH Medicines Formulary, donepezil, rivastigmine and memantine are listed and indicated for use in AD while only rivastigmine is indicated for PDD. Refer to **Appendix 8** on **Pharmacological Treatment of Dementia**.

#### 4.2.1 Alzheimer’s Disease

**Donepezil**

- **Cognition**
  - **All disease severity**
In a Cochrane systematic review of moderate quality RCTs, donepezil 10 mg was more effective than placebo at 24 - 26 weeks in AD across all severity based on MMSE (MD=1.05, 95% CI 0.73 to 1.37). Birks JS et al., 2018, level I

ii. Mild to moderate severity
Donepezil 10 mg/day was more effective than placebo in mild to moderate AD at 24 - 26 weeks based on Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) (MD= -2.67, 95% CI -3.31 to -2.02). Birks JS et al., 2018, level I

Donepezil 5 mg/day was more effective than placebo in moderate AD at 12 - 24 weeks based on MMSE (MD=1.22, 95% CI 0.54 to 1.90). Birks JS et al., 2018, level I

iii. Severe
Benefit in cognitive function was seen with donepezil 10 mg/day compared with placebo in severe AD based on Severe Impairment Battery (SIB) (MD=5.92, 95% CI 4.53 to 7.31). Birks JS et al., 2018, level I

There was no difference in the outcome between donepezil 5 mg/day and 10 mg/day at 24 weeks based on MMSE or SIB. However, the outcome was in favour for 10 mg/day for ADAS-Cog at 24 weeks (MD= -1.05, 95% CI -1.80 to -0.30). Birks JS et al., 2018, level I

b. Safety
Mild adverse events (AEs), namely nausea, vomiting and diarrhoea, were higher in PWD on donepezil 10 mg/day: Birks JS et al., 2018, level I

- compared with 5 mg/day at 26 weeks (OR=1.56, 95% CI 1.07 to 2.28)
- compared with placebo at 24 weeks (OR=1.59, 95% CI 1.23 to 2.05)

There was no difference seen between donepezil 5 mg/day and placebo at 24 weeks.

Rivastigmine
a. Cognition
In another Cochrane systematic review of moderate quality evidence, rivastigmine 6 to 12 mg/day twice daily or 9.5 mg/day patch improved cognition in mild to moderate AD at 26 weeks compared with placebo based on MMSE (WMD=0.74, 95% CI 0.52 to 0.97) and ADAS-Cog test score (WMD= -1.79, 95%CI -2.21 to -1.37).

MMSE results were in favour of rivastigmine (twice daily capsules) compared with placebo at 26 weeks at the following dosages: Birks JS et al., 2015, level I

- 1 - 4 mg/day (WMD=0.43, 95% CI 0.08 to 0.78)
- 6 - 12 mg/day (WMD=0.82, 95% CI 0.56 to 1.08)

Benefit was also seen in MMSE for rivastigmine patch compared with placebo in AD at 24 weeks for different dosages: Birks JS et al., 2015, level I

- 20 cm² (17.4 mg/day) patch (MD=0.90, 95% CI 0.32 to 1.48)
- 10 cm² (9.5 mg/day) patch (WMD=0.64, 95% CI 0.26 to 1.02)

However, no difference was seen in MMSE in similar comparison using rivastigmine 5 cm² (4.6 mg/day) patch.

Rivastigmine 10 cm² (9.5 mg/day) patch vs 6 to 12 mg/day twice daily capsules showed no difference in MMSE for AD at 24 weeks. Birks JS et al., 2015, level I

In an RCT comparing rivastigmine 13.3 mg/ 24 h patch vs 4.6 mg/24 h patch in severe AD, the higher dose patch was superior to lower dose in terms of cognition by SIB at 16 weeks (p<0.0001) and 24 weeks (p<0.0001).
• global function by Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC) (p=0.0023)

However, there was no difference in behaviour using NPI-12.

b. **Safety**

In terms of tolerability, rivastigmine 6 to 12 mg/day twice daily capsules or 9.5 mg/day patch had at least one AE compared with placebo at 26 weeks (OR=2.16, 95% CI 1.82 to 2.57). At these doses, the transdermal patch may have fewer side effects than the capsules but comparable effectiveness.\(^1\)

Apart from that, 20 cm\(^2\) (17.4 mg/24 h) patch had higher incidence of at least one AE (OR=2.28, 95% CI 1.64, 3.16) than 10 cm\(^2\) (9.5 mg/24 h) patch (OR=1.63, 95% CI 1.29 to 2.06) when they were compared with placebo.\(^1\)

The incidence of AEs is greater with 13.3 mg/24 h (15 cm\(^2\)) patch than 9.5 mg/24 h (10 cm\(^2\)) patch (75.0% vs 68.2% respectively). Most of the AEs are mild and decrease over time.\(^2\)

**Galantamine**

An HTA of variable quality evidence showed a benefit in ADAS-Cog from galantamine compared with placebo at:\(^3\)

- 12 - 16 weeks (WMD= -2.39, 95% CI -2.80 to -1.97)
- 21 - 26 weeks (WMD= -2.96, 95% CI -3.41 to -2.51)

Benefit was also seen in behaviour based on NPI at 21 - 26 weeks (WMD= -1.46, 95% CI -2.59 to -0.34). There were higher percentage of AEs in galantamine compared with placebo which were mainly gastrointestinal.

A network meta-analysis of moderate quality studies found superior effectiveness of galantamine 24 mg daily compared with placebo in mild to moderate AD (SMD= -0.50, 95% CI -0.61 to -0.40).\(^4\)

NICE recommends the three AChEIs (donepezil, galantamine and rivastigmine) as monotherapy options for managing mild to moderate AD.\(^5\)

**Memantine**

a. **Cognition**

i. **Mild**

A Cochrane systematic review found no difference between memantine and placebo based on ADAS-Cog (SMD= -0.03, 95% CI -0.19 to 0.13) and Clinician’s Interview-Based Impression of Change (CIBIC+) (SMD= -0.08, 95% CI -0.27 to 0.12).\(^6\)

ii. **Moderate to Severe**

In the same review as above, moderate- to low-certainty evidence showed that memantine was more effective than placebo based on SIB (SMD= -0.27, 95% CI -0.34 to -0.21) and CIBIC+ (SMD= -0.20, 95% CI -0.28 to -0.13).\(^7\)

iii. **Moderate to Severe ± AChEI**

Sub-analysis based on AChEI use showed that memantine was also effective against placebo based on:\(^8\)

- SIB
  - with AChEI (SMD= -0.24, 95% CI -0.33 to -0.14)
  - without AChEI (SMD= -0.33, 95% CI -0.43 to -0.23)
- CIBIC+
  - with AChEI (SMD= -0.21, 95% CI -0.32 to -0.09)
without AChEI (SMD= -0.20, 95% CI -0.30 to -0.10)

b. Safety
The same Cochrane systematic review found no difference between memantine and placebo in the number of people with at least one AE, regardless of dementia aetiology or severity (RR=1.03, 95% CI 1.00 to 1.06). McShane R et al., 2019, level I

Another meta-analysis showed no difference between memantine and placebo in AD based on:

- AEs (OR=1.05, 95% CI 0.88 to 1.25)
- serious AEs (OR=0.89, 95% CI 0.70 to 1.13)
- mortality (OR=1.03, 95% CI 0.74 to 1.44)

NICE recommends memantine monotherapy as an option in:

- moderate AD where there is intolerance or contraindication to AChEI
- severe AD

<table>
<thead>
<tr>
<th>Recommendation 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Donepezil should be offered in Alzheimer’s Disease (AD) of all severity.</td>
</tr>
<tr>
<td>• Rivastigmine is an option in mild to moderate AD.</td>
</tr>
<tr>
<td>• Memantine may be considered in moderate to severe AD as monotherapy or in combination with acetylcholinesterase inhibitors.</td>
</tr>
</tbody>
</table>

4.2.2 Vascular Dementia

Donepezil

a. Cognition
In vascular dementia, donepezil is significantly more effective than placebo based on:Román GC et al., 2010, level I

- V-ADAS-cog at 12, 18 and 24 weeks (p<0.05)
- MMSE at 24 weeks (p=0.0301)

c. Safety
Donepezil is well tolerated; most adverse events are transient and mild to moderate in severity.Román GC et al., 2010, level I

Rivastigmine

a. Cognition
A Cochrane systematic review found benefit in MMSE (MD=0.60, 95% CI 0.11 to 1.09) with rivastigmine (3 - 12 mg/day) compared with placebo in probable vascular dementia at 24 weeks. There was no significant difference betweenBirks J et al., 2013, level I

- rivastigmine 6 mg/day and placebo in MMSE for subcortical vascular dementia
- rivastigmine 3 - 9 mg/day and placebo in ADAS-Cog for MCI and cognitive impairment no dementia (CIND)

b. Safety
There were significantly higher rates of vomiting, nausea, diarrhoea and anorexia in rivastigmine compared with placebo.Birks J et al., 2013, level I

Memantine

a. Cognition
A Cochrane systematic review found probable small benefit favouring memantine against placebo based on ADAS-Cog (MD= -2.15, 95% CI -3.25 to -1.05). McShane R et al., 2019, level I
b. Behaviour
The same review showed low certainty evidence favouring memantine against placebo based on Nurses' Observation Scale for Geriatric Patients (NOSGER) (SMD= -0.20, 95% CI -0.37 to -0.03). McShane R et al., 2019, level I.

c. Safety
Refer to Subchapter 4.2 A (Memantine - Tolerability).

Donepezil, rivastigmine, galantamine and memantine comparison

a. Cognition
In a network meta-analysis on vascular cognitive impairment, donepezil 10 mg/day and rivastigmine 6 mg/day were superior than placebo based on MMSE with MD of 0.84 (95% CI 0.14 to 1.57) and 1.37 (95% CI 0.22 to 2.53) respectively. The derived dose-based hierarchy of the cognitive enhancers' efficacy was as follows: rivastigmine 6 mg > donepezil 10 mg > donepezil 5 mg > rivastigmine 12 mg > memantine 20 mg > placebo. Meanwhile the derived dose-based hierarchy based on ADAS-cog were: memantine 20 mg > galantamine 24 mg > donepezil 10 mg > donepezil 5 mg > rivastigmine 12 mg > placebo > rivastigmine 9 mg. Jin BR et al., 2019, level I.

b. Safety
The derived hierarchy of the risk of total AEs was donepezil 10 mg > galantamine > donepezil 5 mg > memantine > placebo > rivastigmine. Jin BR et al., 2019, level I.

NICE recommends only to consider AChEI or memantine for people with vascular dementia if they have suspected co-morbid Alzheimer's disease, Parkinson's disease dementia or dementia with Lewy bodies. NICE, 2018

- Patients with vascular dementia with concurrent vascular risk factors should be treated with recommended drugs for the management of the medical problems. MoH, 2009

Recommendation 8
- Acetylcholinesterase inhibitors or memantine may be considered in vascular dementia.

4.2.3 Lewy Body Disease (Dementia with Lewy Body/Parkinson's Disease Dementia)
Acetylcholinesterase inhibitors
a. Cognition
A Cochrane systematic review of six moderate quality RCTs showed an improvement in the MMSE favouring treatment with AChEI (rivastigmine and donepezil) compared with control in DLB, PDD and cognitive impairment in Parkinson's disease (CIND-PD) (WMD=1.08, 95% CI 0.50 to 1.66). However, subgroup analysis showed: Rolinski M et al., 2012, level I
- positive effect in PDD (WMD=1.09, 95% CI 0.45 to 1.73) and, PDD and CIND-PD (WMD=1.05, 95% CI 0.42 to 1.68)
- no difference in DLB (WMD=1.24, 95% CI 0.28 to 2.76)

A recent meta-analysis found that results on MMSE and MoCA favoured AChEI (rivastigmine and donepezil) and memantine compared with control in PDD and DLB (SMD=0.46, 95% CI 0.36 to 0.55). Meng YH et al., 2019, level I. The 15 studies used in the meta-analysis were small and short duration but of good quality.

b. Behaviour
Two meta-analyses showed improvement in behaviour outcomes with:
• AChEI compared with control in DLB, PDD and CiND-PD (SMD= -0.20, 95% CI -0.36 to -0.04); the effect was only seen in RCTs using rivastigmine and lasting ≥18 weeks<sup>19</sup> M et al., 2012, level I

• AChEI and memantine compared with control in PDD and DLB (MD= -1.73, 95% CI -2.84 to -0.62)<sup>20</sup> Meng YH et al., 2019, level I

c. **Safety**

In the two meta-analyses mentioned above, treatment groups experienced more adverse events than control groups with:

- OR=1.64, 95% CI 1.26 to 2.15; there was no difference in severe adverse events<sup>19</sup> M et al., 2012, level I

- RR=1.09, 95% CI 1.04 to 1.16<sup>20</sup> Meng YH et al., 2019, level I

Rivastigmine was also found to be less tolerable than donepezil and memantine.

**Memantine**

a. **Cognition**

A Cochrane systematic review found very low certainty evidence that memantine had no difference with placebo based on MMSE.<sup>21</sup> McShane R et al., 2019, level I

b. **Behaviour**

There was no difference between memantine with placebo based on NPI in the same review.<sup>21</sup> McShane R et al., 2019, level I

c. **Safety**

Refer to Subchapter 4.2 A (Memantine - Tolerability).

<table>
<thead>
<tr>
<th>Recommendation 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Rivastigmine or donepezil may be considered for dementia with Lewy body and Parkinson’s disease dementia.</td>
</tr>
</tbody>
</table>

### 4.2.4 Frontotemporal Dementia

**Donepezil**

A systematic review found low level evidence on discontinuation of donepezil resulting in reduction in NPI total and ZBI scores after two weeks of the discontinuation in FTD.<sup>22</sup> Bouli M et al., 2017, level I

**Rivastigmine**

In the same review as above, an open-label study demonstrated amelioration of behavioural changes after 12 months treatment with rivastigmine in patients with a probable diagnosis of FTD.<sup>22</sup> Bouli et al., 2017, level I

**Galantamine**

A systematic review found that galantamine was not effective based on Frontal Behavioural Inventory (FBI), Western Aphasia Battery (WAB), Clinical Global Impressions-severity (CGI-S) and Clinical Global Impressions-improvement (CGI-I) in behavioural variant of FTD (bvFTD).<sup>23</sup> Nardell M et al., 2014, level I

Another systematic review showed that it was also not associated with improvement of psychiatric symptoms in FTD.<sup>22</sup> Bouli M et al., 2017, level I

However, galantamine was found to be well tolerated.<sup>23</sup> Nardell M et al., 2014, level I

**Memantine**

A meta-analysis and two systematic review of RCTs showed that memantine had no significant difference with placebo based on:

• CGI, MMSE, NPI and ZBI<sup>24</sup> Kishi T et al., 2015, level I
Memantine was also found to be well tolerated. McShane R et al., 2019, level I

The lack of effectiveness of memantine discussed above were supported by a later Cochrane systematic review based on MMSE and NPI. McShane R et al., 2019, level I

4.2.5 Behavioural and Psychological Symptoms

a. Effectiveness

Antipsychotics

A systematic review found that antipsychotics (APs) had small but significant effect in reducing BPSD in PWD compared to placebo (SMD = -0.13, 95% CI -0.21 to -0.06). Dyer SM et al., 2017, level I

A network meta-analysis found that risperidone was more effective than placebo in reducing agitation based on agitation rating scale of Cohen-Mansfield Agitation Inventory (CMAI), NPI-A, BEHAVE-AD-A and Neurobehavioral Rating Scale-Agitation (NBRS-A) in PWD (OR=1.96, 95% CI 1.49 to 2.59) but haloperidol appeared less effective compared with nearly all comparators. Kongpakwattana K et al., 2018, level I

Another network meta-analysis on PWD with BPSD compared APs with placebo and showed: Yunusa I et al., 2019, level I

- aripiprazole improved outcomes on NPI (SMD = -0.17, 95% CI -0.31 to -0.02)
- risperidone improved outcomes on CMAI (SMD = -0.26, 95% CI -0.37 to -0.15)

There were no significant differences on effectiveness between the APs.

Two RCTs assessed the effectiveness and safety of brexpiprazole (fixed and flexible doses) compared with placebo on agitation in patients with AD. The first RCT (NCT01862640) showed brexpiprazole 2 mg/day had greater improvement in CMAI Total score at week 12 than placebo (adjusted MD = -3.77, 95% CI -7.38 to -0.17). The second RCT (NCT01922258) on brexpiprazole 0.5 - 2 mg showed no difference in the CMAI Total score at week 12 (adjusted MD = -2.34, 95% CI -5.49 to 0.82). However post-hoc analysis on patients titrated to maximum brexpiprazole dose (2 mg) at week 4 showed improvement in in the score at week 12 (adjusted MD = -5.06, 95% CI -8.99 to -1.13). Grossberg GT et al., 2019, level I

Antidepressants

A systematic review found very low-quality evidence that sertraline did not have significant effect on global BPSD outcomes based on NPI compared with placebo in PWD and concomitant depression. Dyer SM et al., 2017, level I

The above network meta-analysis also showed that selective serotonin reuptake inhibitors as a class reduced BPSD in PWD who developed agitation based on CMAI, NPI-A, BEHAVE-AD-A and NBRS-A (OR=1.61, 95% CI 1.02 to 2.53) compared with placebo. Kongpakwattana K et al., 2018, level I

NICE recommends not to offer antidepressants in mild to moderate depression for people with mild to moderate dementia unless they have pre-existing severe mental health problem. NICE, 2018
Mood stabilisers
A meta-analysis on mood stabilisers as an adjunct to conventional anti-dementia drugs on BPSD in AD suggested a significant effect in favour of placebo over valproate on NPI total (WMD=3.71, 95% CIs 0.15 to 7.26). Xiao H et al., 2010, level I

A Cochrane meta-analysis of moderate-quality evidence of two studies showed no difference between valproate and placebo in total Brief Psychiatric Rating Scale (BPRS) (measuring agitation) in PWD after six weeks of treatment. Baillon SF et al., 2018, level I

Others
In a systematic review, a low quality RCT showed that pain management with analgesics reduced global BPSD in PWD (SMD= -0.24, 95% CI -0.47 to -0.01). Dyer SM et al., 2017, level I

A Cochrane systematic review of small trials found some beneficial effects on sleep from trazodone and orexin antagonist with no harmful effects. McCleery J et al., 2020, level I

A systematic review concluded that benzodiazepine use to be avoided in the elderly based on results from a meta-analysis of 45 RCTs and review of 24 RCTs. Schroeck JL et al., 2016, level I

b. Safety
Non-significant differences in treatment acceptability were observed for nearly all medications when compared with placebo except for oxcarbazepine. Kongpakwattana K et al., 2018, level I

The network meta-analysis which used SUCRAs in its analysis showed:

- for somnolence or sedation: placebo was ranked as the safest, followed by risperidone, aripiprazole and olanzapine while quetiapine was the least safe
- for EPSs: quetiapine and aripiprazole ranked as the safest agents, followed by olanzapine while risperidone was ranked the worst
- for cerebrovascular adverse event: aripiprazole had highest probability of safety among the drugs, followed by quetiapine, risperidone and olanzapine
- for falls, fracture or injury: risperidone and quetiapine ranked in the top two positions for safety, followed by aripiprazole, placebo and olanzapine

The Cochrane meta-analysis of low-quality evidence showed a higher rate of adverse effects among valproate-treated participants compared with controls (OR=2.02, 95% CI 1.30 to 3.14). Baillon SF et al., 2018, level I

Two RCTs found no notable difference in the treatment-emergent adverse events (TEAEs) between brexipiprazole and placebo. The majority of the TEAE were mild or moderate in severity. Grossberg GT et al., 2019, level I

- United States Food and Drug Administration (US FDA) issued a warning regarding increased mortality associated with the use of AP in elderly patients with dementia-related psychosis in response to emerging evidence since 2005. Rubino A et al, 2020, level III
- NICE recommends AP to be offered to PWD who are either at risk of harming themselves or others, or experiencing symptoms that are causing them severe distress. NICE, 2018
- NICE recommends on AP in PWD:
  - the lowest effective dose should be used and for the shortest possible duration
  - should be reassessed regularly and wean off if it is not needed

Recommendation 10
- Antipsychotics may be considered for behavioural and psychological symptoms in people with dementia (PWD) where there is a risk of harming themselves or others.
• Antidepressants:
  o may be considered for PWD who have agitation
  o may be prescribed for PWD with pre-existing severe mental health problem

• There is insufficient evidence to support the use of mood stabilisers to treat agitation in PWD

4.2.6 Anticholinergic Concerns
PWD often have multiple co-morbidities and require multiple pharmacotherapies. Examples of commonly used medications include benzodiazepines, APs and antihistamines. These medications have high anticholinergic burden (ACB) which causes negative outcomes in the patients. Therefore, careful consideration is needed before initiating such medications and, active monitoring and deprescribing should be carried out whenever possible. Refer to Appendix 9 on Anticholinergic Burden Score.

American Geriatric Society on Beer’s criteria consider potentially inappropriate prescription (PIP) as an explicit list of drugs that are best avoided by older adults in most circumstances or under specific situations e.g. in certain diseases or conditions. By the 2019 American Geriatrics Society, 2019, level III

Examples of PIP/psychotropics are:
- first-generation antihistamines (e.g. chlorpheniramine, hydroxyzine)
- antispasmodics (e.g. atropine, hyoscine)
- antipsychotics
- antidepressants
- benzodiazepines
- gastrointestinal medication (e.g. metoclopramide, proton pump inhibitors)
- non-steroidal anti-inflammatory drugs

A systematic review of 26 studies found prevalence of PIP in the range of 13 - 74% for PWD. Hukin D et al., 2019, level II-2

In a meta-analysis, the prevalence of PIP was lower in PWD living in the community compared with those in nursing homes and specialised care homes [31% (95% CI 9 to 52) vs 42% (95% CI 30 to 55)]. Delgado J et al., 2020, level II-2

A cross-sectional study showed that an average ACB score >3 during the first three months initiation of AChEI in PWD increased the risk of:
- treatment modification at one year (HR=1.12, 95% CI 1.02 to 1.24)
- delirium at one year (HR=1.52, CI 1.17 to 1.96)
- mortality at two years (HR=1.23, CI 1.06 to 1.41)

NICE recommends to consider minimising the use of medicines associated with increased ACB and look for alternatives wherever possible. NICE, 2018

**Recommendation 11**
- The use of anticholinergic medications in dementia should be done cautiously with regular review of indication and deprescribed whenever possible.

Refer to Algorithm 3 on Treatment of Dementia.
Refer to Appendix 10 on Suggested Guide to Review and Deprescribe (PIP/Psychotropic) in Dementia.

5. TRADITIONAL AND COMPLEMENTARY MEDICINE

There is no strong evidence on the effectiveness and safety of Traditional and Complementary Medicine (TCM) in the treatment of dementia.

In a meta-analysis on PWD, extract of Ginkgo biloba (EGb761) of 240 mg/day improved.\textsuperscript{1}\textsuperscript{Tan MS et al., 2015, level I}

- cognitive function (WMD= -3.19, 95% CI -3.56 to -2.83)
- ADL (SMD= -0.45, 95% CI -0.55 to -0.36)
- global assessment of change (OR=2.47, 95% CI 1.91 to 3.20)
- behavioural symptoms (WMD= -4.82, 95% CI -5.44 to -4.20)

However, there was significant heterogeneity among the primary papers. On safety, there were no significant differences between EGb761 and placebo in the proportion of participants experiencing any adverse events or serious adverse events for whole group and subgroup analysis.

Another meta-analysis did not indicate a higher bleeding risk associated with standardised ginkgo biloba extract compared with placebo. However, the study population was not entirely on dementia and the primary papers were mostly of moderate/high risk of bias.\textsuperscript{2}\textsuperscript{Kellermann AJ et al., 2015, level I}

A Cochrane systematic review found low-certainty evidence that melatonin doses up to 10 mg may have little or no effect on any major sleep outcome over eight to 10 weeks in people with AD and sleep disturbances.\textsuperscript{3}\textsuperscript{McCleery J et al., 2020, level I} Another meta-analysis of seven RCTs (mainly moderate quality primary papers) showed melatonin prolonged total sleep time at night (SMD=0.26, 95% CI 0.01 to 0.51) compared with placebo in AD patients. However, there was no significant difference in sleep efficacy between melatonin and placebo (SMD= 0.14, 95% CI -0.17 to 0.44).\textsuperscript{4}\textsuperscript{Wang YY et al., 2017, level I}

A Cochrane review could not conclude on the effectiveness and safety of traditional chinese herbal medicine for VaD due to poor reporting and trial methodology of the primary papers.\textsuperscript{5}\textsuperscript{Chan ESY et al., 2018, level I}

There is insufficient evidence to support curcumin supplementation as an effective means of both preventing and treating dementia and symptoms of cognitive decline.\textsuperscript{6}\textsuperscript{Seddon N et al., 2019, level I}

- There is insufficient evidence to recommend the use of TCM in the treatment of dementia.

6. MILD COGNITIVE IMPAIRMENT

Mild cognitive impairment (MCI) is a condition in which individuals present with cognitive impairment but minimal impairment of instrumental activities of daily living (IADL). Those with MCI/CIND have greater risk of developing all types of dementia (RR=3.3, 95% CI 2.5 to 4.5) compared with age-matched participants with no MCI after 2 - 5 years of follow-up.\textsuperscript{7}\textsuperscript{Petersen RC et al., 2018}
a. Diagnostic Criteria
DSM-5 recognises the predementia stage of cognitive impairment. The condition, which has many features of MCI, is termed mild neurocognitive disorder. Mild neurocognitive disorder recognises subtle features of cognitive impairment that are distinct from ageing but do not represent dementia.\textsuperscript{DSM-5}

b. Assessment Tools
It is important to have a baseline cognitive measurement on MMSE or any cognitive assessment tools for patients with MCI. Majority of the tools available have cultural, religion and education bias. Thus, the interpretation of the result is individually tailored to each patient. When initial assessment is normal, clinicians can proceed to neuropsychological test to confirm the diagnosis of MCI. If both assessments are normal, the subject is recognised as having subjective memory complaint.

c. Investigation
In MCI, the investigations required are similar as in dementia in order to rule out other conditions. Refer to Chapter 3 on Diagnosis and Assessment.

d. Non-pharmacological Interventions
MCI is a subjective complaint of deteriorating memory. After managing the modifiable risk factors and deprescribing cognitive suppression medication, it is advisable for patients to undergo non-pharmacological therapy.

- Cognitive enhancing therapy
Multimodal Enhancing Cognitive Therapy involved multiple non-pharmacological intervention that support the ability to maintain cognitive function. It is an intervention to improve cognitive function in cognitively normal person. These interventions improve and maintain cognitive function, thus reduce the progression of cognitive deterioration.\textsuperscript{Han JW et al., 2017, level I}

Although cognitive enhancing therapy have been accepted in the management of MCI, a systematic review failed to show significant objective improvement with it.\textsuperscript{Huckans M et al., 2013, level I}

- Exercise
Aerobic exercise is known to have cognition-enhancing effects. A small RCT on adults with amnestic MCI showed that high-intensity aerobic exercise improved performance of multiple test of executive function in women, while favourable effects were seen only on Trails B performance in men.\textsuperscript{Baker LD et al., 2010, level I}

- Diet and supplement
In a systematic review of heterogenous evidence, there was some improvements in performance, particularly in memory, with the most consistent results shown by B vitamins in MCI. However, there was no significant effect on progression from MCI to dementia and/or AD with supplementation of vitamin E, ginkgo biloba or Fortasyn Connect.\textsuperscript{McGrattan AM et al., 2018, level I}

e. Pharmacological Interventions
There is no recent evidence supporting the use of pharmacological treatment in managing MCI.\textsuperscript{Petersen RC et al., 2018}

- Follow-up of patients with MCI is done with serial assessment to monitor their cognitive status.
- There is insufficient evidence to recommend the use pharmacological intervention in MCI.
7. **SPECIAL POPULATION**

The management of certain populations with early-onset cognitive impairment is aimed at preventing further deterioration or sequelae of the cognitive function. This is done with AChEIs or specific pharmacological intervention specific to the causes as well as non-pharmacological measures. These populations include those with acquired brain injury, alcohol-related dementia (ARD) and HIV-associated neurocognitive disorders (HANDs).

7.1 **Acquired Brain Injury**

In a Cochrane systematic review on chronic cognitive impairment (≥12 months post-injury) in traumatic brain injury (TBI), rivastigmine significantly improved only one primary measure i.e. verbal memory functioning compared with placebo. There was no significant difference in safety profile. Dougall D et al., 2015, level II

Two Cochrane systematic reviews on non-pharmacological interventions in acquired brain injury showed:

- cognitive rehabilitation was not effective compared to no intervention or conventional rehabilitation in improving return to work, independence in activities of daily living (ADL), community integration or quality of life for adults with TBI. Kumar KS et al., 2017, level I.
- music interventions may be beneficial on communication (SMD=0.75, 95% CI 0.11 to 1.39), naming (MD=9.79, 95% CI 1.37 to 18.21) and speech repetition (MD=8.90, 95% CI 3.25 to 14.55) in persons with post-stroke aphasia compared with control. However, these findings were based on a small number of studies with small sample sizes. MageeWL et al., 2017, level II.

7.2 **Alcohol-related Dementia**

The prevalence of ARD ranges from 0.12% to 25.6% with more males being affected. It occurs more consistently at approximately 10% in early-onset dementia compared with the more scarce data in late-onset dementia. Cheng C et al., 2017, level II.

Heavy alcohol use could cause ARD from:

- direct neurotoxic effect with permanent structural and functional brain damage
- thiamine deficiency leading to Wernicke-Korsakoff syndrome
- risk factor for other conditions that could also damage the brain (e.g. hepatic encephalopathy in patients with cirrhotic liver disease)
- cardiovascular diseases resulting indirectly in vascular dementia

Two systematic reviews on the treatment of ARD showed:

- for persons with alcohol dependence and Wernicke-Korsakoff syndrome with no triad of acute symptoms, intramuscular (IM) thiamine at 200 mg/day for two consecutive days was more effective than 5 mg/day on working memory performance using the delayed alternation test (MD= -17.90, 95% CI -35.4 to -0.40). Day E et al., 2013, level I.
- with the use of extra processing time, explicit encouragement to generate associations and extra retrieval time, persons with Korsakoff’s syndrome performed similarly to healthy population on associative verbal learning procedure. Svanberg J et al., 2013, level II.

However, the primary papers used in the two reviews had some methodological limitations.

7.3 **HIV-Associated Neurocognitive Disorders**

There are different diagnostic approaches for HANDs e.g. 2007 Frascati criteria, Global Deficit Score and Clinical Mental State Examinations. Among all, the 2007 Frascati criteria is the most widely used diagnostic criteria for HANDs. Wang Y et al., 2020, level II.

and it consists of three categories:

- Asymptomatic Neurocognitive Impairment (ANI) – mild neurocognitive impairment in at least two cognitive domains but not affecting daily functions
• Mild Neurocognitive Disorder (MND) – mild neurocognitive impairment in at least two cognitive domains and has mild interference with daily functions
• HIV-associated Dementia (HAD) – severe neurocognitive impairment in at least two cognitive domains and has marked difficulty with daily functions

The prevalence of HANDs ranged from 39.1% to 44.4% according to a meta-analysis on global disease burden of it. MND and HAD were shown to be lower in patients with higher level of income, current CD4 count and proportion on Anti-Retroviral Therapy (ART). These findings suggested that early ART initiation to maintain a high level of CD4 cell count and prevent severe immunosuppression was likely to reduce the prevalence and severity of HANDs. *Wang Y et al., 2020, level II-2*

A meta-analysis on cognitive screening tools to diagnose HANDs showed that HIV Dementia Scale and International HIV Dementia Scale had generally poor (0.48) and moderate (0.62) pooled sensitivities. Thus, both were not ideal tools for identifying a range of neurocognitive impairment in HIV patients. *Zipursky AR et al., 2013, level III*

Apart from that, the primary papers were of moderate quality and the heterogeneity was significant.

Every ART agent has different CPE (Central Nervous System [CNS] Penetration Effectiveness) score and use of combined agents with higher CPE score may be associated with better neurocognitive outcome. An RCT showed that one unit increase in the CPE score was associated with an increase in the Composite Neuropsychology Z Score (NPZ3) score among HANDs patients with >3 antiretroviral drugs in the regimen (change in NPZ3 score=0.07, 95% CI 0.02 to 0.12). *Smurzynski M et al., 2011, level I*

• In the above special populations, the causes of cognitive impairment should be managed accordingly to prevent further complications. As such cases occur more often in those younger than 65 years old, apart from addressing the cognitive issues, greater psychological and social support are needed for them in terms of employment, finances and social life.
• There is insufficient evidence on the effectiveness of AChEI or memantine in these special populations.

8. CAREGIVER SUPPORT

Caring for PWD can be emotionally and physically challenging. The role of caregiver is a central and integral part of dementia management. Caregivers should be involved in the management of PWD from the beginning. *Moh, 2009* NICE recognises the important role of caregivers and discusses their involvement in the management of PWD in detail. *NICE, 2018*

• The ZBI has good reliability and validity to assess burden of caregivers for PWD. *Whalen KJ & Buchholz SW, 2009, level III*

A few interventions to reduce the burden/strain of caregivers have been studied and are discussed below.

a. Respite care

Respite care is any intervention designed to give rest or relief to caregivers. A Cochrane review showed no significant difference in caregiver burden between respite care and control. However, polarity therapy reduced caregivers perceived stress compared with respite care (MD=5.80, 95% CI 1.43 to 10.17). *Maayan N et al., 2014, level I*
An Australian guidelines on dementia recommends that PWD, their carers and family should be offered respite appropriate to their needs which include in-home respite, day respite, planned activity groups and residential respite. \textit{Australian Guidelines, 2016}

\textbf{b. Carer training}
A meta-analysis showed that multicomponent interventions for caregivers significantly delayed institutionalisation after 6 - 12 months post-intervention compared with minimal support or usual care in mild to moderately severe AD. The intervention among others comprised of education and support for caregivers. \textit{Olazaran J et al., 2010, level I}

NICE also recommends to offer psychoeducation and skills training to carers of PWD. These include: \textit{NICE, 2018}

- education about dementia on its symptomatology and natural progression
- development of personalised strategies and carer skills
- training on care of PWD, including understanding and responding to changes in behaviour
- training in communication skills
- advice on carers’ own physical, mental health and spiritual wellbeing
- information on relevant services and their access
- advice on planning for the future

\textbf{c. Spirituality and religious support}
Spiritual and religious support may be useful for caregivers to improve their coping strategy and reduce emotional distress. However, some caregivers might experience negative effect with this intervention. \textit{Giannouli V et al., 2020, level II-2} Therefore, it should be individualised according to the caregivers preference and acceptance.

\begin{center}
\textbf{Recommendation 12}
\begin{itemize}
  \item Caregivers should be actively involved and supported in the management of dementia.
    \begin{itemize}
      \item This includes assessment of the burden of caregivers.
    \end{itemize}
\end{itemize}
\end{center}

There are various community health and support services that are available in the country to assist PWD and their caregivers. Social and Welfare Department are involved in some of these services. Relevant information can be obtained from the Ministry of Women, Family and Community Development of Malaysia and related non-governmental organisations (NGOs).

Stigmatisation, lack of awareness and perceived lack of credibility of healthcare workers are among factors that discourage caregivers from reaching out to available services and supports. \textit{Nikmat AW et al., 2011, level III}

Hence, collaborative efforts should be made by the government and respective stakeholders, including the MoH, Social and Welfare Department and NGOs to provide better support and service for the PWDs in Malaysia.

Refer to \textbf{Appendix 11 on Important Points for Caregiver of People with Dementia} and \textbf{Appendix 12 on Useful Resources}.

\section{9. LEGAL AND ETHICAL ISSUES}

The key to a person’s right of autonomy is adequate decision-making capacity. In Malaysia, when a person is deemed to be mentally disordered and is incapable of managing oneself and
one’s affairs, the provisions of the Mental Health Act 2001 (Part X: Section 51-Section 75) can be applied. The Act aims to protect the person from his or her own harmful decisions or actions.

a. Decision-making capacity
The key to a person’s right of autonomy is possessing adequate decision-making capacity. If a PWD’s decision-making capacity is intact, doctors need to respect the autonomy of the PWD to decide on treatment options. If a PWD lacks decision-making capacity, then a surrogate decision-maker will need to make decisions for the PWD based on his/her best interest. The following points need to be taken into account:

- Decision-making capacity is determined with regard to specific tasks and decisions that need to be made. PWD’s can be judged to have capacity to make certain decisions, and not having capacity for other decisions at the same time. Lo B, 2015, level III
- If there is any doubt regarding a PWD’s decision-making capacity, a formal assessment of decision-making capacity should be carried out. The assessment should be properly documented in the patient’s notes.
- Where appropriate, efforts should be taken to restore the patient’s decision-making capacity or encourage the PWD’s involvement in the decision-making process.
- If the Mental Health Act 2001 is used, Section 77 is applicable when obtaining consent.

b. Advance directives
Although there is no law in Malaysia to govern advance directives in respect of healthcare matters, the common law right to refuse treatment is applicable. Chan HY, 2019, level III Making advance decisions can be immensely valuable as it can help healthcare providers in Malaysia to understand better the preferences and wishes of their patients. Tan MKM, 2018, level III PWD may decide to make advance decisions regarding treatment while they still possess the mental capacity to do so by way of an advance directive or an advance care plan (Section 10d). Advance directives serve to guarantee the right of mentally competent individuals to continue exercising their autonomy in the event of future incapacity. These include the following:

- A doctor should comply with a patient’s unequivocal written directive to refuse a particular treatment. MMC, 2017
- Doctors are advised to consult the next of kin or seek legal advice if there is doubt on the validity of an advance directive, and these discussions need to be documented. MMC, 2017

Allan CL et al., 2016, level III

For patients who decide to stop driving or who are forced to stop, clinicians must discuss practical alternatives, the impact on psychosocial benefits and the loss of autonomy with patients and their caregivers.

Allan CL et al., 2016, level III

- Assessment of fitness to drive involves composite cognitive test batteries in combination with other types of assessments e.g. driving simulator test or on-road test. Allan CL et al., 2016, level III
- Locally, an assessment of fitness to drive can be done by referring the patient to an occupational therapist with the prescribed form (Borang Pemeriksaan Kesihatan)
It is the responsibility of a PWD to report his/her disability to the authorities for licensing purposes. However, medical practitioners may voluntarily report new cases of disability to the Road Transport Department. It is good medical practice to seek the PWD's consent for such reporting. However, if the PWD does not consent to the disclosure, medical practitioners may still permissibly breach the confidentiality of the PWD utilising reasons for disclosure in the patient's medical interests and/or disclosure in the public interest if they judge that doing so will provide important benefits to the patient or prevent serious harm to third parties. Such disclosures should be limited only to essential information for the intended purpose and only to those persons who need to be notified.

**Recommendation 13**
- If there is any doubt regarding people with dementia (PWD)’s decision-making capacity, a formal assessment of decision-making capacity should be carried out.
- A doctor should comply with a patient’s unequivocal written directive to refuse a particular treatment if that decision was made while the patient had mental capacity.
- PWD (particularly moderate to severe) should be assessed for their driving ability if they still wish to drive.

10. **PALLIATIVE AND END-OF-LIFE CARE**

There has been no major breakthrough in curative treatment for dementia over the past few decades. As dementia is a progressive and irreversible illness which can affect the QoL for PWD and their caregivers, palliative care should be initiated at the time of diagnosis throughout different stages of illness. As the disease progressed and the PWD become more dependent, the palliative care components should be more emphasised in their management to achieve the best quality of life.

Continuous communication with the PWD and caregivers is important to assist them to establish the advance care planning especially during early stage of disease where the PWD are still capable to make their own decision. Education, spiritual and psychological support should be offered to improve QoL and reduce burden of the caregivers.

Evidence for best practice during end-of-life care for PWD is limited and heterogenous. Nevertheless, best supportive care should be offered to them based on their preference and the principles of basic medical ethics.

a. **Artificial nutrition and hydration**

Dysphagia is a common problem in advance dementia. In a systematic review, dysphagia diagnostic assessment e.g. clinical swallowing examination, video fluoroscopy swallowing study and flexible endoscopic examination of swallowing can be used to determine the type of deficits in oropharyngeal dysphagia. However, there was limited evidence on the benefits of postural change, diet and liquid modification, and medication in management of this condition. In another systematic review, there was moderate quality of evidence on the use of high-calorie supplements to improve weight gain in person with advance dementia and not on function and survival. There was limited evidence to show that enteral tube feeding may prolong the survival rate and reduce aspiration pneumonia in advanced dementia based on a systematic review. On the other hand, percutaneous enterogastrostomy tube was
associated with increased risk of pressure ulcer development or aggravation. \cite{Salomon_ALR_2015}

NICE does not recommend routine use of enteral feeding in people with severe dementia, unless indicated for a potentially reversible co-morbidity. \cite{NICE_2018}

- There was insufficient evidence to recommend enteral feeding in patients with severe dementia. Thus, the choice of oral or enteral feeding in severe dementia depends on the clinician after discussion with caregivers and taking into consideration PWD’s wish or advance directives.

b. Pain management

Pain is another prevalent and distressing issue for person with advance dementia. However, the affected person is not able to express themselves accurately on the pain they experience and very often it is manifested as behavioural problems.

An RCT examining on the impact of a stepwise protocol for treating pain on PWD in nursing home showed that pain medication significantly improved pain control in the intervention group. \cite{Sandvik_RK_2014} However a systematic review showed that evidence on pain management for advance dementia was limited and heterogenous. Despite increased use of analgesia, pain was still prevalent in PWD. \cite{Husebo_BS_2016}

c. Restraints

Restraints are used to protect people with severe dementia from harming themselves because of their behaviour. These can be physical, chemical or psychological restraints.

A multinational cohort study on PWD in nursing homes showed that physical restraint was associated with a higher risk of both functional (RR=2.30, 95% CI 1.52 to 3.49) and cognitive decline (RR=1.93, 95% CI 1.44 to 2.58) compared with AP alone. These risks were even higher among residents receiving both AP and physical restraints with RR of 2.49 (95% CI 1.89 to 3.27) and 2.31 (95% CI 1.54 to 3.48) respectively. \cite{Foebel_AD_2016}

A Belgian evidence-based guidelines on older adults in home care recommend that physical restraints should be avoided as much as possible due to the negative physical and psychosocial consequences to the patient. \cite{Scheepmans_K_2020}

d. Advance care planning

Every PWD has the right to plan ahead for their future when they still have the capability to make decision. Hence, advance care planning should be discussed with PWD and their family members as early as possible after the diagnosis is established. The discussion should include lasting power of attorney (for decisions unrelated to healthcare as permitted under the Power of Attorney Act 1949) and future medical care direction based on their own preference, value and goals of life. PWD and their family members are allowed to review and change any advance statements they have made as the disease progresses. \cite{NICE_2018}

A systematic review showed that intervention with advance care planning significantly reduced inappropriate hospital admissions and health care costs for PWD compared with control group. \cite{Robinson_L_2012} Therefore, attending clinicians should actively offer advance care planning to PWD and their family members when they are ready for it. Refer to Appendix 13 on Advance Care Planning for more details.
**Recommendation 14**
- Physical restraints should be avoided in dementia.
- Advance care planning should be considered in the management of dementia once the diagnosis is established.

11. **REFERRAL**

Patients suspected of dementia should be referred to specialist care centres (e.g. geriatrics/psychiatry/neurology) for confirmation of diagnosis and management of complexities. This is because of the need for comprehensive assessments and investigations. At the moment, medication for dementia is not available at primary care locally.

Once a diagnosis is made, stable PWD can be co-managed in both primary and secondary/tertiary care as an integrated care system. Management aspect than can be offered in primary care include management of medical co-morbidities and non-pharmacological treatment (e.g. cognitive stimulation and designing meaningful activities). However, these cases should be referred back to secondary/tertiary care when there is difficult behaviour problem, psychiatric co-morbidity, rapid deterioration in clinical condition, etc.

**Recommendation 15**
- All patients with suspected dementia should be referred to a geriatric psychiatrist/psychiatrist, geriatrician or neurologist for assessment, diagnosis and management.

12. **IMPLEMENTING THE GUIDELINES**

The management of dementia should be guided by an evidence-based approach, in order to provide quality care to the PWD. Several factors may affect the implementation of recommendations in the CPG.

12.1 **Facilitating and Limiting Factors**

Existing facilitators for application of the recommendations in the CPG include:
- wide dissemination of the CPG (soft- and hardcopies) to healthcare providers
- training and updates in relation to dementia
- public awareness campaigns related to cognitive impairment including dementia
- inter-ministerial collaboration and involvement of non-governmental organisations to support the PWD and their caregivers

Existing barriers for application of the recommendations of the CPG are:
- limited exposure and training among healthcare providers on management of dementia
- variation in availability of expertise and access to service provision
- lack of awareness among patients, families, community and healthcare workers
- lack of local data on dementia, e.g. research, registry, etc., for planning on services

12.2 **Potential Resource Implications**

In local setting, dementia is very much underdiagnosed due to lack of awareness and misconception that it is normal part of ageing among the public and healthcare providers. Besides that, PWD always present late with behavioural issues.
In terms of pharmacotherapy, AChEI is strongly recommended in the treatment of dementia. However, it is not readily available in the primary/secondary/tertiary care due to financial constraints. Apart from that, many non-pharmacological interventions may not be easily available due to lack of manpower/expertise to conduct it.

The CPG recommends early detection and referral, comprehensive assessment and treatment of the disorder. This requires increased awareness among public, caregivers and healthcare providers to establish diagnosis and early intervention to PWD as well as support to the caregivers.

Thus, the implementation of this CPG requires resources to provide:
- training of healthcare providers and caregivers
- better access to referral centres
- better caregiver support network
- access to policy makers e.g. National Dementia Action Plan

Based on the key recommendations, the following are proposed as clinical audit indicators for quality management of dementia:

Percentage of patients with suspected dementia referred to a relevant specialist* for assessment and diagnosis = \[
\frac{\text{Number of patients with suspected dementia referred to a relevant specialist* for assessment and diagnosis in a period}}{\text{Number of patients with suspected dementia in the same period}}
\]

Percentage of newly diagnosed Alzheimer’s Disease** offered = \[
\frac{\text{Number of newly diagnosed Alzheimer’s Disease** offered donepezil or rivastigmine in a period}}{\text{Number of newly diagnosed Alzheimer’s Disease** in the same period}}
\]

*geriatric psychiatrist/psychiatrist, geriatrician or neurologist
**all severity

Implementation strategies will be developed following the approval of the CPG by MoH which include launching of the CPG, Quick Reference and Training Module.
REFERENCES

42. Handing EP, Andel R, Kadlecova P, et al. Midlife Alcohol Consumption and Risk of Dementia Over 43 Years of Follow-Up: A Population-Based Study From the Swedish Twin Registry. The
journals of gerontology Series A, Biological sciences and medical sciences. 2015;70(10):1248-54.
64. Law ZK, Todd C, Mehraram R, et al. The Role of EEG in the Diagnosis, Prognosis and Clinical Correlations of Dementia with Lewy Bodies-A Systematic Review. Diagnostics (Basel, Switzerland). 2020;10(9).


112. Sooryanarayana R, Sazlina SG. 


114. Svanberg J, Evans JJ. 

115. Tan Klak Min M. 


118. Tsai KK, Chan JY, Hirai HW, et al. 


120. Van der Steen JT, Smaling HJ, van der Wouden JC, et al. 

121. Vilela VC, Pacheco RL, Latorraca COC, et al. 


123. Whalen KJ, Buchholz SW. 
The reliability, validity and feasibility of tools used to screen for caregiver burden: a systematic review. JBI library of systematic reviews. 2009;7(32):1373-430.


125. World Health Organization. 

126. World Health Organization. 
Dementia Fact Sheet. 2020.

127. World Health Organization. Tobacco Fact Sheet 2020


EXAMPLE OF SEARCH STRATEGY

Clinical Question: What are the safe and effective pharmacological treatments for dementia? - Acetylcholinesterase inhibitors (rivastigmine, donepezil, galantamine) & NMDA antagonists (memantine)

1. DEMENTIA/
2. dementia*.tw.
3. (familial adj1 dementia*).tw.
4. (senile adj2 paranoid dementia*).tw.
5. DEMENTIA, VASCULAR/
6. (acute onset adj3 vascular dementia*).tw.
7. ((arteriosclerotic or vascular) adj1 dementia*).tw.
8. (subcortical adj2 arteriosclerotic encephalopathy*).tw.
9. (binswanger* adj2 (encephalopath* or disease*)).tw.
10. chronic progressive subcortical encephalopathy.tw.
11. (subcortical adj2 vascular dementia*).tw.
12. (subcortical arteriosclerotic adj2 encephalopath*).tw.
13. (chronic progressive adj3 subcortical encephalopath*).tw.
14. (subcortical adj1 leukoencephalopath*).tw.
15. FRONTOTEMPORAL DEMENTIA/
16. ((frontotemporal or frontotemporal lobe) adj2 dementia*).tw.
17. (frontotemporal dementia adj4 (parkinsonism or parkinsonism 17 or parkinsonism-17)).tw.
18. ((grn-related or grn related) adj3 frontotemporal dementia*).tw.
19. ((ubiquitin positive or ubiquitin-positive) adj3 frontotemporal dementia*).tw.
20. (frontotemporal lobar degeneration adj6 (ubiquitin positive inclusion or ubiquitin-positive inclusion)).tw.
21. (semantic adj1 dementia*).tw.
22. familial pick* disease*.tw.
23. ftd-grn.tw.
24. ftd-pgrn.tw.
25. ftdp-17.tw.
26. ftd-17 grn.tw.
27. ftd with tdp 43 pathology.tw.
28. ftd with tdp-43 pathology.tw.
29. ftd-tdp.tw.
30. DEMENTIA, MULTI-INFARCT/
31. (lacunar adj1 dementia*).tw.
32. ((multiinfarct or multi infarct or multi-infarct) adj2 dementia*).tw.
33. ALZHEIMER DISEASE/
34. alzheimer* dementia*.tw.
35. (alzheimer* disease adj2 (early onset or late onset or focal onset)).tw.
36. (familial adj2 alzheimer* disease).tw.
37. ((Alzheimer* type or Alzheimer-type) adj3 (dementia* or senile dementia*)).tw.
38. ((senile or presenile) adj1 dementia*).tw.
39. (primary senile degenerative adj3 dementia*).tw.
40. presenile alzheimer dementia.tw.
41. Mixed dementia*.tw.
42. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41
43. CHOLINESTERASE INHIBITORS/
44. (anticholinesterase* or anti cholinesterase* or anti-cholinesterase*).tw.
45. ((acetylcholinesterase or cholinesterase) adj1 inhibitor*).tw.
46. (irreversible adj2 cholinesterase inhibitor*).tw.
47. ((reversible or irreversible) adj2 cholinesterase inhibitor*).tw.
48. RIVASTIGMINE/
49. Exelon.tw.
50. (rivastigmine adj2 hydrogen tartrate).tw.
51. rivastigmine tartrate.tw.
52. Rivastigmine.tw.
53. GALANTAMINE/
54. galanthamine hydrobromide.tw.
55. donepezil.tw.
56. aricept.tw.
57. MEMANTINE/
58. ebixa.tw.
59. memantin*.tw.
60. or/43-59
61. 42 and 60
62. limit 61 to (yr="2009 -Current" and "all adult (19 plus years)" and English and humans)
63. limit 62 to systematic reviews
Appendix 2

CLINICAL QUESTIONS

1. What are the risk factors for dementia?
2. What are the risk reduction interventions/strategies for dementia?
3. What are the diagnostic criteria for dementia?
4. What are the accurate assessment tools for dementia?
5. What are the accurate assessment tools for non-cognitive domains in dementia?
6. What are the safe and effective pharmacological treatments for dementia?
   - Acetylcholinesterase inhibitors (rivastigmine, donepezil, galantamine) & NMDA antagonists (memantine)
   - Antipsychotics/antidepressants/mood stabilisers for BPSD
   - Drugs to use with caution (anticholinergic burden)
7. What are the safe and effective non-pharmacological treatments for dementia?
8. What are the safe and effective TCM for dementia?
9. What are the safe and effective treatment in mild cognitive impairment?
10. What are the safe and effective palliative care for dementia?
11. What are the basic social, legal and ethical issues in dementia?
12. What are the safe and effective interventions for caregivers of dementia?
13. What are the safe and effective management in the following special groups of dementia?
   - Acquired brain injury
   - Alcohol-related dementia
   - HIV-associated neurocognitive disorder
14. When should patients with dementia be referred to a tertiary specialist service?
10 WARNING SIGNS OF DEMENTIA

1. Memory Loss

2. Difficulty performing familiar tasks

3. Problems with language

4. Disorientation to time and place

5. Poor or decreased judgement

6. Problems keeping track of things

7. Misplacing things

8. Changes in mood and behaviour

9. Trouble with images and spatial relationships

10. Withdrawal from work or social activities

Dementia is not a part of normal ageing. Talk to a doctor or contact Alzheimer's Disease Foundation Malaysia (ADFM) for more information.

Source: Alzheimer's Disease Foundation Malaysia (Available at: http://adfm.org.my/10-warning-signs/)
INITIAL ASSESSMENT TOOLS

a. Abbreviated Mental Test Score (AMTS)

The following questions are put to the patient. Each question correctly answered scores one point:

<table>
<thead>
<tr>
<th>Question</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>What is your age? (1 point)</td>
<td></td>
</tr>
<tr>
<td>What is the time to the nearest hour? (1 point)</td>
<td></td>
</tr>
<tr>
<td>Give the patient an address, and ask him or her to repeat it at the end of the test. (1 point) e.g. 42 West Street</td>
<td></td>
</tr>
<tr>
<td>What is the year? (1 point)</td>
<td></td>
</tr>
<tr>
<td>What is the name of the hospital or number of the residence where the patient is situated? (1 point)</td>
<td></td>
</tr>
<tr>
<td>Can the patient recognize two persons (the doctor, nurse, home help, etc.)? (1 point)</td>
<td></td>
</tr>
<tr>
<td>What is your date of birth? (day and month sufficient) (1 point)</td>
<td></td>
</tr>
<tr>
<td>In what year did World War 1 begin? (1 point) (other dates can be used, with preference for dates some times in the past)</td>
<td></td>
</tr>
<tr>
<td>Name the present monarch/prime minister/president. (1 point)</td>
<td></td>
</tr>
<tr>
<td>Count backwards from 20 down to 1. (1 point)</td>
<td></td>
</tr>
</tbody>
</table>

A score of 6 or less suggests delirium or dementia, although further tests are necessary to confirm the diagnosis.
b. Mini-Cog

The Mini-Cog

1. Instruct the patient to listen carefully and repeat the following:

   APPLE       WATCH       PENNY

2. Administer the Clock Drawing Test (CDT)

3. Ask the patient to repeat the three words given previously.

   __________  __________  __________

Scoring:
Number of correct items recalled _______ [if 3 then negative screen. STOP]

If answer is 1-2
   Is CDT Abnormal?   No       Yes

If No, then negative screen
   If Yes, then screen positive for cognitive impairment.

Instructions for CDT:
Inside the circle draw the hours of a clock as if a child would draw them. Place the hands of
the clock to represent the time "forty-five minutes past ten o'clock"
Appendix 5

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDER FIFTH EDITION (DSM-5)

Diagnostic criteria for major neurocognitive disorder (or dementia)

A. Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor or social cognition) based on:
   1. Concern of the individual, a knowledgeable informant or the clinician that there has been a significant decline in cognitive function; and
   2. A substantial impairment in cognitive performance, preferably documented by standardised neuropsychological testing or in its absence, another quantified clinical assessment.

B. The cognitive deficits interfere with independence in everyday activities (that is, at a minimum, requiring assistance with complex instrumental activities of daily living such as paying bills or managing medications).

C. The cognitive deficits do not occur exclusively in the context of a delirium.

D. The cognitive deficits are not better explained by another mental disorder.

Specify:
- Without behavioural disturbance: if the cognitive disturbance is not accompanied by any clinically significant behavioural disturbance.
- With behavioural disturbance (specify disturbance): if the cognitive disturbance is accompanied by a clinically significant behavioural disturbance (for example, psychotic symptoms, mood disturbance, agitation, apathy or other behavioural symptoms). For example, major depressive disorder or schizophrenia.

Diagnostic criteria for mild neurocognitive disorder

A. Evidence of modest cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor or social cognition) based on:
   1. Concern of the individual, a knowledgeable informant or the clinician that there has been a mild decline in cognitive function; and
   2. A modest impairment in cognitive performance, preferably documented by standardised neuropsychological testing or in its absence, another quantified clinical assessment.

B. The cognitive deficits do not interfere with capacity for independence in everyday activities (that is, complex instrumental activities of daily living such as paying bills or managing medications are preserved, but greater effort, compensatory strategies or accommodation may be required).

C. The cognitive deficits do not occur exclusively in the context of a delirium.

D. The cognitive deficits are not better explained by another mental disorder (for example, major Depressive Disorder or Schizophrenia).

Dementia

F00 Dementia in Alzheimer's disease
   F00.0 Dementia in Alzheimer's disease with early onset
   F00.1 Dementia in Alzheimer's disease with late onset
   F00.2 Dementia in Alzheimer's disease, atypical or mixed type
   F00.9 Dementia in Alzheimer's disease, unspecified

F01 Vascular dementia
   F01.0 Vascular dementia of acute onset
   F01.1 Multi-infarct dementia
   F01.2 Subcortical vascular dementia
   F01.3 Mixed cortical and subcortical vascular dementia
   F01.8 Other vascular dementia
   F01.9 Vascular dementia, unspecified

F02 Dementia in other diseases classified elsewhere
   F02.0 Dementia in Pick's disease
   F02.1 Dementia in Creutzfeldt-Jakob disease
   F02.2 Dementia in Huntington's disease
   F02.3 Dementia in Parkinson's disease
   F02.4 Dementia in human immunodeficiency virus [HIV] disease
   F02.8 Dementia in other specified diseases classified elsewhere

F03 Unspecified dementia

A fifth character may be added to specify dementia in F00-F03, as follows:
   .x0 Without additional symptoms
   .x1 Other symptoms, predominantly delusional
   .x2 Other symptoms, predominantly hallucinatory
   .x3 Other symptoms, predominantly depressive
   .x4 Other mixed symptoms

Dementia

A general description of dementia is given here, to indicate the minimum requirement for the diagnosis of dementia of any type, and is followed by the criteria that govern the diagnosis of more specific types.

Dementia is a syndrome due to disease of the brain, usually of a chronic or progressive nature, in which there is disturbance of multiple higher cortical functions, including memory, thinking, orientation, comprehension, calculation, learning capacity, language and judgement. Consciousness is not clouded. Impairments of cognitive function are commonly accompanied and occasionally preceded, by deterioration in emotional control, social behaviour or motivation. This syndrome occurs in Alzheimer's disease, in cerebrovascular disease and in other conditions primarily or secondarily affecting the brain.

In assessing the presence or absence of a dementia, special care should be taken to avoid false-positive identification: motivational or emotional factors, particularly depression, in addition to motor slowness and general physical frailty, rather than loss of intellectual capacity, may account for failure to perform.
Dementia produces an appreciable decline in intellectual functioning and usually some interference with personal activities of daily living, such as washing, dressing, eating, personal hygiene, excretory and toilet activities. How such a decline manifests itself will depend largely on the social and cultural setting in which the patient lives. Changes in role performance, such as lowered ability to keep or find a job, should not be used as criteria of dementia because of the large cross-cultural differences that exist in what is appropriate and because there may be frequent, externally imposed changes in the availability of work within a particular culture.

If depressive symptoms are present but the criteria for depressive episode (F32.0-F32.3) are not fulfilled, they can be recorded by means of a fifth character. The presence of hallucinations or delusions may be treated similarly.

.x0 Without additional symptoms
.x1 Other symptoms, predominantly delusional
.x2 Other symptoms, predominantly hallucinatory
.x3 Other symptoms, predominantly depressive
.x4 Other mixed symptoms

THE GLOBAL DETERIORATION SCALE FOR ASSESSMENT OF PRIMARY DEGENERATIVE DEMENTIA

The Global Deterioration Scale (GDS), developed by Dr. Barry Reisberg, provides caregivers an overview of the stages of cognitive function for those suffering from a primary degenerative dementia e.g. AD. It is broken down into seven different stages. Stages 1 - 3 are the pre-dementia stages while Stages 4 - 7 are the dementia stages. Beginning in stage 5, an individual can no longer survive without assistance. Within the GDS, each stage is numbered (1 - 7), given a short title (i.e., forgetfulness, early confusional, etc. followed by a brief listing of the characteristics for that stage. Caregivers can get a rough idea of where an individual is at in the disease process by observing that individual's behavioural characteristics and comparing them to the GDS. For more specific assessments, use the accompanying Brief Cognitive Rating Scale (BCRS) and the FAST measures.

<table>
<thead>
<tr>
<th>Level</th>
<th>Clinical Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1</strong></td>
<td><strong>No cognitive decline</strong></td>
</tr>
<tr>
<td></td>
<td>No subjective complaints of memory deficit. No memory deficit evident on clinical interview.</td>
</tr>
<tr>
<td><strong>2</strong></td>
<td><strong>Very mild cognitive decline (Age Associated Memory Impairment)</strong></td>
</tr>
<tr>
<td></td>
<td>Subjective complaints of memory deficit, most frequently in the following areas: (a) forgetting where one has placed familiar objects; (b) forgetting names one formerly knew well. No objective evidence of memory deficit on clinical interview. No objective deficits in employment or social situations. Appropriate concern with respect to symptomatology.</td>
</tr>
<tr>
<td><strong>3</strong></td>
<td><strong>Mild cognitive decline (Mild Cognitive Impairment)</strong></td>
</tr>
<tr>
<td></td>
<td>Earliest clear-cut deficits. Manifestations in more than one of the following areas: (a) patient may have gotten lost when traveling to an unfamiliar location; (b) co-workers become aware of patient's relatively poor performance; (c) word and name finding deficit becomes evident to intimates; (d) patient may read a passage or a book and retain relatively little material; (e) patient may demonstrate decreased facility in remembering names upon introduction to new people; (f) patient may have lost or misplaced an object of value; (g) concentration deficit may be evident on clinical testing. Objective evidence of memory deficit obtained only with an intensive interview. Decreased performance in demanding employment and social settings. Denial begins to become manifest in patient. Mild to moderate anxiety accompanies symptoms.</td>
</tr>
<tr>
<td></td>
<td>Moderate cognitive decline (Mild Dementia)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>4</td>
<td>Moderately severe cognitive decline (Moderate Dementia)</td>
</tr>
<tr>
<td>5</td>
<td>Severe cognitive decline (Moderately Severe Dementia)</td>
</tr>
<tr>
<td>Stage</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
</tr>
<tr>
<td>7</td>
<td>Very severe cognitive decline (Severe Dementia)</td>
</tr>
</tbody>
</table>

All verbal abilities are lost over the course of this stage. Frequently there is no speech at all, only unintelligible utterances and rare emergence of seemingly forgotten words and phrases. Incontinent of urine, requires assistance toileting and feeding. Basic psychomotor skills, e.g., ability to walk, are lost with the progression of this stage. The brain appears to no longer be able to tell the body what to do. Generalised rigidity and developmental neurologic reflexes are frequently present.

## Appendix 7b

**FUNCTIONAL ASSESSMENT STAGING (FAST)**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Level of Functioning</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><strong>No difficulty</strong>, either subjectively or objectively</td>
</tr>
<tr>
<td>2</td>
<td>Complains of forgetting location of objects. <strong>Subjective work difficulties.</strong></td>
</tr>
<tr>
<td>3</td>
<td>Decreased job functioning evident to co-workers. Difficulty in traveling to new locations. <strong>Decreased organisational capacity</strong></td>
</tr>
<tr>
<td>4</td>
<td><strong>Decreased ability to perform complex tasks</strong>, e.g. planning dinner for guests, handling personal finances (e.g. forgetting to pay bills), difficulty in marketing, etc.*</td>
</tr>
<tr>
<td>5</td>
<td><strong>Requires assistance in choosing proper clothing</strong> to wear for the day, season or occasion, e.g. patient may wear the same clothing repeatedly unless supervised.*</td>
</tr>
<tr>
<td>6a</td>
<td><strong>Improperly putting on clothes without assistance or cuing</strong> (e.g. may put street clothes on over night-clothes or shoes on wrong feet or have difficulty buttoning clothing) occasionally or more frequently over the past weeks.*</td>
</tr>
<tr>
<td>6b</td>
<td>Unable to bathe (shower) properly (e.g. <strong>difficulty adjusting bath-water (shower temperature)</strong>) occasionally or more frequently over the past weeks.*</td>
</tr>
<tr>
<td>6c</td>
<td><strong>Inability to handle mechanics of toileting</strong> (e.g. forgets to flush the toilet, does not wipe properly or properly dispose of toilet tissue) occasionally or more frequently over the past weeks.*</td>
</tr>
<tr>
<td>6d</td>
<td><strong>Urinary incontinence</strong> (occasionally or more frequently over the past weeks).*</td>
</tr>
<tr>
<td>6e</td>
<td><strong>Faecal incontinence</strong> (occasionally or more frequently over the past weeks).*</td>
</tr>
<tr>
<td>7a</td>
<td><strong>Ability to speak limited to approximately a half a dozen intelligible different words or fewer</strong>, in the course of an average day or in the course of an intensive interview.</td>
</tr>
<tr>
<td>7b</td>
<td>Speech ability limited to the use of a <strong>single intelligible word</strong> in an average day or in the course of an interview (the person may repeat the word over and over).</td>
</tr>
<tr>
<td>7c</td>
<td><strong>Ambulatory ability lost</strong> (<strong>cannot walk without personal assistance</strong>).</td>
</tr>
<tr>
<td>7d</td>
<td><strong>Cannot sit up without assistance</strong> (e.g., the individual will fall over if there are no lateral rests [arms] on the chair).</td>
</tr>
<tr>
<td>7e</td>
<td><strong>Loss of ability to smile.</strong></td>
</tr>
<tr>
<td>7f</td>
<td><strong>Loss of ability to hold up head independently.</strong></td>
</tr>
</tbody>
</table>

*Scored primarily on the basis of information obtained from a knowledgeable informant and/or caregiver.

**FAST** scoring instructions:

The **FAST Stage** is the highest consecutive level of disability. For clinical purposes, in addition to staging the level of disability, additional non-ordinal (non-consecutive) deficits should be noted since these additional deficits are of clear clinical relevance.

# MEDICATIONS USED FOR THE TREATMENT OF DEMENTIA

<table>
<thead>
<tr>
<th>Name</th>
<th>Dosing (mg/day)</th>
<th>Liver impairment</th>
<th>Renal impairment</th>
<th>Common adverse effects</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetylcholinesterase Inhibitors (AChEI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Donepezil</strong></td>
<td>Initial: 5 mg once daily, may increase to 10 mg once daily after 4 - 6 weeks</td>
<td>No dosage adjustment necessary</td>
<td>No dosage adjustment necessary</td>
<td>Gastrointestinal (GI): diarrhoea, nausea, vomiting</td>
<td>Use with caution in patients: 1. at risk of prolonged cardiac repolarisation. 2. sick-sinus syndrome, bradycardia or conduction abnormalities. 3. with risk factors for rhabdomyolysis 4. at risk of peptic ulcer disease 5. with chronic obstructive pulmonary disease (COPD) and/or asthma 6. with history of seizure disorder 7. with bladder outlet obstruction/prostatic hyperplasia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Central nervous system (CNS): insomnia, fatigue, drowsiness</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cardiovascular: chest pain, hypertension, syncope</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Miscellaneous: Accidental injury</td>
<td></td>
</tr>
<tr>
<td><strong>Rivastigmine</strong></td>
<td>Oral: Initial: 1.5 mg twice daily; may increase by 3 mg daily every 2 weeks (based on tolerability)</td>
<td>No dosage adjustment necessary</td>
<td>No dosage adjustment necessary</td>
<td>Nausea, vomiting, diarrhoea</td>
<td>Use with caution in patients with: 1. CNS depression 2. allergic dermatitis 3. extrapyramidal effects 4. sick-sinus syndrome, bradycardia or other supraventricular conduction abnormalities (Vagotonic effects) 5. at risk of peptic ulcer disease 6. COPD 7. history of seizure disorder 8. bladder outlet obstruction/prostatic hyperplasia</td>
</tr>
<tr>
<td></td>
<td>Transdermal: Child-Pugh class A and B: Initial and maximum dose of 4.6 mg/24 hours</td>
<td>No dosage adjustment necessary</td>
<td>Oral: No dosage adjustment necessary</td>
<td>CNS: dizziness, headache, falls</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Transdermal: Child-Pugh class C: No dosage adjustment</td>
<td>Transdermal: No dosage adjustment necessary</td>
<td>Oral: No dosage adjustment necessary</td>
<td>Endocrine and metabolic: weight loss</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Local: Application site erythema (transdermal)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Neuromuscular and skeletal: tremor</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cardiovascular: Hypertension, syncope</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Initial Dose</td>
<td>Dosing Schedule</td>
<td>Dose Adjustments</td>
<td>Adverse Effects</td>
<td>Precautions</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------</td>
<td>-----------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Galantamine</td>
<td>Initial: 4 mg twice daily for 4 weeks</td>
<td>If tolerated, increased to 8 mg twice daily for more than 4 weeks</td>
<td>If tolerated, increase to 12 mg twice daily</td>
<td>*If treatment interrupted &gt;3 days, to restart at lowest dose</td>
<td>Moderate: Max dose 16 mg/day&lt;br&gt;Mild to moderate impairment: No dosage adjustment necessary&lt;br&gt;Severe impairment: Use with caution</td>
</tr>
<tr>
<td>Memantine</td>
<td>Initial: 5 mg once daily; increase dose by 5 mg every week as tolerated to a target maximum dose of 20 mg/day</td>
<td>Dose may be administered once daily or two divided doses</td>
<td>Mild to moderate impairment: No dosage adjustment necessary&lt;br&gt;Severe impairment: Use with caution</td>
<td>Cardiovascular: hypertension&lt;br&gt;CNS: dizziness, confusion, headache, fatigue&lt;br&gt;GI: diarrhoea, constipation, vomiting&lt;br&gt;Genitourinary: urinary incontinence&lt;br&gt;Infection: influenza&lt;br&gt;Neuromuscular and skeletal: back pain&lt;br&gt;Respiratory: cough, dyspnoea</td>
<td>Hypersensitivity have been reported. Advise patients to report skin reactions immediately. Use with caution in patients with: 1. cardiovascular disease&lt;br&gt;2. hepatic impairment&lt;br&gt;3. ophthalmic disease&lt;br&gt;4. renal impairment&lt;br&gt;5. seizure disorder</td>
</tr>
</tbody>
</table>

**N-methyl-D-aspartate (NMDA) receptor antagonist**
tolerated, may titrate up to a target dose of 5 mg twice daily

**NOTE:** All these medications are currently OFF-LABEL based on MoH National Formulary and National Pharmaceutical Regulatory Agency (NPRA)

### Antipsychotics

<table>
<thead>
<tr>
<th>Name</th>
<th>Dosing (mg/day)</th>
<th>Liver impairment</th>
<th>Renal impairment</th>
<th>Common adverse effects</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aripiprazole</td>
<td>Agitation/aggression and psychosis associated with dementia, severe or refractory: Initial: 2 - 5 mg once daily; may increase dose based on response and tolerability in 5 mg increments at intervals ≥1 week up to 15 mg once daily In severe agitation associated with dementia with Lewy bodies, antipsychotics are generally avoided; if use is required, titrating above 2 - 5 mg/day is not recommended</td>
<td>No dosage adjustment necessary</td>
<td>No dosage adjustment necessary</td>
<td>Increased serum glucose, weight gain, constipation, nausea, vomiting, agitation, akathisia, anxiety, drowsiness, extrapyramidal reaction, fatigue, headache, sedation, insomnia, tremor</td>
<td>1. Suicidal thinking/behaviour 2. Cardiovascular disease 3. Dementia 4. Parkinson's Disease 5. Seizures</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>Agitation/aggression and psychosis associated with dementia, severe or refractory: Initial: 2.5 mg once daily, may increase dose based on response and tolerability in increments of 2.5 - 5 mg/day at intervals ≥1 week up to 10 mg/day No dosage adjustment except when used in combination with fluoxetine (as separate components) when initial olanzapine dose should be Use with caution (cases of hepatitis and liver injury have been reported with olanzapine use).</td>
<td>No dosage adjustment necessary</td>
<td>No dosage adjustment necessary</td>
<td>Orthostatic hypotension, Increased LDL, triglyceride &amp; serum cholesterol, increased serum glucose, increased serum prolactin, weight gain, constipation, dyspepsia, increased appetite, xerostomia, decreased serum bilirubin, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, akathisia, dizziness, drowsiness, extrapyramidal</td>
<td>1. Cardiovascular disease 2. Hepatic impairment 3. Dementia 4. Parkinson's Disease 5. Seizures 6. Renal Impairment</td>
</tr>
<tr>
<td>Drug</td>
<td>Indication</td>
<td>Dose and Administration</td>
<td>Adverse reactions</td>
<td>Interactions</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| **Quetiapine** | Agitation/aggression and psychosis associated with dementia, severe or refractory: Initial: 25 mg at bedtime; may increase dose gradually (e.g. weekly) based on response and tolerability up to 75 mg twice daily | IR tablet: Initial: 25 mg once daily; increase dose by 25 to 50 mg/day to effective dose, based on individual clinical response and tolerability  
ER tablet: Initial: 50 mg once daily; increase dose by 50 mg once daily to effective dose, based on individual clinical response and tolerability  | Reaction, fatigue, headache, insomnia, parkinsonism, asthenia  | Increased diastolic blood pressure, increased systolic blood pressure, orthostatic hypotension, tachycardia, decreased HDL cholesterol, increased serum cholesterol, increased serum triglycerides, weight gain, increased appetite, xerostomia, decreased haemoglobin, agitation, dizziness, drowsiness, extrapyramidal reaction, fatigue, headache, withdrawal syndrome  |
|            |                                                                            | No dosage adjustment necessary  | Removal by dialysis unlikely.  | 1. Cancer  
2. Impaired gastrointestinal motility  
3. Hepatic impairment  
4. Seizures  
5. Urinary retention  |

**Risperidone**  
Agitation/aggression and psychosis associated with dementia, severe or refractory: Initial: 0.5 mg/day in two divided doses; may increase dose based on response and tolerability in increments of 0.5 mg/day at intervals ≥2 days up to 1 mg/day  
Severe impairment (Child-Pugh class C): Initial: 0.5 mg twice daily; titration should progress slowly in increments of no more than 0.5 mg twice daily; increases to dosages >1.5 mg twice daily should occur at intervals of ≥1 week  
Severe impairment (CrCl <30 ml/minute): initial: 0.5 mg twice daily; titrate slowly in increments of no more than 0.5 mg twice daily; increases to dosages >1.5 mg twice daily should occur at intervals of ≥1 week  
Hyperprolactinaemia, weight gain, increased appetite, nausea, upper abdominal pain, urinary incontinence, akathisia, anxiety, dizziness, drooling, drowsiness, drug-induced extrapyramidal reaction, fatigue, headache, insomnia, parkinsonism, sedation, tremor, cough, nasopharyngitis, rhinorhrea, fever  
1. Cardiovascular disease  
2. Hepatic impairment  
3. Dementia  
4. Seizures  
5. Renal Impairment  

mg=milligramme, GI=gastrointestinal, CNS=central nervous system, IR=immediate release, ER=extended release, CrCl=creatinine clearance, LDL=low density lipoprotein, HDL=high density lipoprotein

Source:  
## ANTICHOLINERGIC BURDEN SCORE

### Drugs with ACB Score of 1

<table>
<thead>
<tr>
<th>Alimemazine</th>
<th>Clidinium</th>
<th>Fluvoxamine</th>
<th>Nifedipine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alverine</td>
<td>Clorazepate</td>
<td>Haloperidol</td>
<td>Paliperidone</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>Codeine</td>
<td>Hydralazine</td>
<td>Prenisnone</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>Colchicine</td>
<td>Hydrocortisone</td>
<td>Quinidine</td>
</tr>
<tr>
<td>Asenapine</td>
<td>Desloratadine</td>
<td>Iloperidone</td>
<td>Ranimidine</td>
</tr>
<tr>
<td>Atenolol</td>
<td>Diazepam</td>
<td>Isoxorbide</td>
<td>Risperdone</td>
</tr>
<tr>
<td>Bupropion</td>
<td>Digoxin</td>
<td>Levocetirizine</td>
<td>Theophylline</td>
</tr>
<tr>
<td>Captopril</td>
<td>Dipyridamole</td>
<td>Loperamide</td>
<td>Trazodone</td>
</tr>
<tr>
<td>Cetirizine</td>
<td>Disopyramide</td>
<td>Loratadine</td>
<td>Triamterene</td>
</tr>
<tr>
<td>Chlorthalidone</td>
<td>Fentanyl</td>
<td>Metoprolol</td>
<td>Venlafaxine</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>Furosemide</td>
<td>Morphine</td>
<td>Warfarin</td>
</tr>
</tbody>
</table>

### Drugs with ACB Score of 2

<table>
<thead>
<tr>
<th>Amantadine</th>
<th>Cyclobenzaprine</th>
<th>Meperidine</th>
<th>Nefopam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belladonna</td>
<td>Cyproheptadine</td>
<td>Methotrimeprazine</td>
<td>Oxcarbazepine</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Loxapine</td>
<td>Molindone</td>
<td>Pimozide</td>
</tr>
</tbody>
</table>

### Drugs with ACB Score of 3

<table>
<thead>
<tr>
<th>Amitriptyline</th>
<th>Darifenacin</th>
<th>Imipramine</th>
<th>Propiverine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxapine</td>
<td>Desipramine</td>
<td>Meclizine</td>
<td>Quetiapine</td>
</tr>
<tr>
<td>Atropine</td>
<td>Dicyclomine</td>
<td>Methocarbamol</td>
<td>Scopolamine</td>
</tr>
<tr>
<td>Benztopine</td>
<td>Dimenhydrinate</td>
<td>Nortriptyline</td>
<td>Solifenacin</td>
</tr>
<tr>
<td>Brompheniramine</td>
<td>Diphenhydramine</td>
<td>Olanzapine</td>
<td>Thioridazine</td>
</tr>
<tr>
<td>Carboxamine</td>
<td>Doxepin</td>
<td>Orphenadrine</td>
<td>Tolerodine</td>
</tr>
<tr>
<td>Chlorpheniramine</td>
<td>Doxylamine</td>
<td>Oxybutynin</td>
<td>Trifluoperazine</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>Fesoterodine</td>
<td>Paroxetine</td>
<td>Trihexyphenidyl</td>
</tr>
<tr>
<td>Clemastine</td>
<td>Flavoxate</td>
<td>Perphenazine</td>
<td>Trimipramine</td>
</tr>
<tr>
<td>Clo mipramine</td>
<td>Hydroxyzine</td>
<td>Promethazine</td>
<td>Tropium</td>
</tr>
<tr>
<td>Clozapine</td>
<td>Hyoscyamine</td>
<td>Propantheline</td>
<td>Trihexyphenidyl</td>
</tr>
</tbody>
</table>

### Categorical Scoring

- Possible anticholinergics include those listed with a score of 1
- Definite anticholinergics include those listed with a score of 2 or 3

### Numerical Scoring

- Add the score contributed to each selected medication in each scoring category.
- Add the number of possible or definite anticholinergic medications.

### Notes

- Each definite anticholinergic may increase the risk of cognitive impairment by 46% over six years.
- For each one-point increase in the ACB total score, a decline in MMSE score of 0.33 points over two years has been suggested.
- Additionally, each one-point increase in the ACB total score has been correlated with a 26% increase in the risk of death.

### Criteria for Categorisation

**Score of 1**: Evidence from in vitro data that chemical entity has antagonist activity at muscarinic receptor

**Score of 2**: Evidence from literature, prescriber’s information or expert opinion of clinical anticholinergic effect

**Score of 3**: Evidence from literature, expert opinion, or prescriber’s information that medication may cause delirium

### Source

SUGGESTED GUIDE TO REVIEW AND DEPRESCRIBE (POTENTIALLY INAPPROPRIATE PRESCRIPTION/PSYCHOTROPIC) IN DEMENTIA

Step 1: Evaluation

<table>
<thead>
<tr>
<th>Does the patient have more than one (PIP/psychotropic)?</th>
<th>□ No □ Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Has the patient been on (PIP/psychotropic) &gt;3 months?</td>
<td>□ No □ Yes</td>
</tr>
</tbody>
</table>

- If YES for at least one of the above, kindly proceed to Step 2.

Step 2: PIP/Pychotropic Review

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Description</th>
<th>Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td>Is there a justified reason?</td>
<td>□ No</td>
</tr>
<tr>
<td>Effectiveness</td>
<td>Has it been effective for the indication?</td>
<td>□ No</td>
</tr>
<tr>
<td></td>
<td>Is it the recommended choice for the indication?</td>
<td>□ No</td>
</tr>
<tr>
<td>Safety</td>
<td>Is there therapeutic duplication?</td>
<td>□ No</td>
</tr>
<tr>
<td></td>
<td>Is there any contraindication(s) to the patient?</td>
<td>□ No</td>
</tr>
<tr>
<td></td>
<td>Is there a potential or actual and significant drug interaction?</td>
<td>□ No</td>
</tr>
<tr>
<td></td>
<td>Is this regime a result of prescribing cascade?</td>
<td>□ No</td>
</tr>
<tr>
<td>Pharmacotherapy</td>
<td>Is the dose appropriate?</td>
<td>□ No</td>
</tr>
<tr>
<td></td>
<td>Is the frequency appropriate?</td>
<td>□ No</td>
</tr>
</tbody>
</table>

- If YES for any one of the above, kindly proceed to Step 3.

Step 3: PIP/psychotropic Reconciliation

Kindly consider the following actions for this patient:
1. Deprescribing PIP/psychotropic
2. Substituting to a better alternative
3. Modify the regime (dose, frequency and duration, etc.)
4. Consider potential for managing all symptoms with a single PIP/psychotropic
## IMPORTANT POINTS FOR THE CAREGIVER OF PEOPLE WITH DEMENTIA

### 1. UNDERSTANDING DEMENTIA
- The caregivers need to understand about dementia and the importance of early detection and early diagnosis.

### 2. SUPPORT FOR CAREGIVERS/CARERS
- Caring the PWD may cause stress to family and caregivers. Build-up of stress may lead to emotional problems and poor health of the caregivers. One of the ways to relieve the stress is to have someone to listen to them, e.g. using telephone counselling service or participating in support group events which are tailored to their needs. The support group should also involve other family members as well.
- Caregiver should be aware of their own physical and mental health issues e.g. increased risk of depression and over tiredness. Therefore, respite care should be offered for adequate support to help caregivers in coping with caring for PWD.

### 3. RECOGNISE FUNDAMENTAL NEEDS OF CARE FOR PWD

#### a. Recognise the stress and challenges faced by PWD and suggested carer responses
- PWD feel stressed when they are unable to recall what has just happened. They may also be disorientated to time, place and person. Though their memory, understanding and judgement are declining, their emotion may still be intact.

#### b. Learn to engage with PWD

<table>
<thead>
<tr>
<th>i. Forgetfulness:</th>
<th>Helpful tips: Courteously answer the questions because PWD have difficulty to recall and may be repeatedly asking question for confirmation as a result of being anxious.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PWD do not recall what they talked about and with whom they talked.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ii. Disorientated to time, place and person:</th>
<th>Helpful tips: PWD may have problems organising and making plans and, executing things correctly. Confirm with them the actions that they are doing and ask what they want to do next step by step.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PWD may repeatedly ask the day, date, where they are and who the persons around them.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>iii. Impaired understanding and judgement:</th>
<th>Helpful Tips: Engage in the activity together with PWD. For example, instead of allowing person with dementia to cook, let them do simple things like washing vegetables or peeling onions and, at the same time ensuring their safety.</th>
</tr>
</thead>
<tbody>
<tr>
<td>For instance, PWD may become unable to cook, use remote control for television or operate the washing machine.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>iv. Delusion:</th>
<th>Helpful tips: Caregiver should show interest in looking for the item together with the PWD. Once search is done, distract the activity by saying for e.g. ‘We have tried searching for the item, but can’t find it, let’s have a cup of tea and look again later’.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A false belief that is beyond challenge. For instance, PWD may have delusion of theft, that is the false belief that their valuable thing, e.g. money or purse, has been stolen by someone despite being reassured that this does not occur.</td>
<td></td>
</tr>
</tbody>
</table>

| v. Wandering: | Helpful tips: Person with dementia may have their own reason to go out. The carer can try to engage by asking “where are you going” and “why are you going?” Carer may then help them to achieve their purpose. It is also useful to put a name tag with their name, address and |
vi. **Anger:**
PWD may suddenly get upset and become verbally or physically agitated. They can be sensitive to certain conversations and may become angry and restless as they are unable to express their feelings and difficulties.

**Helpful tips:**
Carers will need to be more accommodating and avoid triggers or situations that hurt their feelings.

### c. Understand important daily life activities of PWD

<table>
<thead>
<tr>
<th>Activity</th>
<th>Description</th>
<th>Helpful tips</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>i. Eating:</strong></td>
<td>PWD often forget they have eaten and may also not recognise edible/food items from nonedible items</td>
<td><strong>Helpful tips:</strong> Explain regarding timing of meals by mentioning actual time. Avoid having nonedible items within reach for those who cannot tell the difference.</td>
</tr>
<tr>
<td><strong>ii. Bathing:</strong></td>
<td>PWD may not be co-operative to take bath; They may refuse to undress, wash themselves or dress after their bath</td>
<td><strong>Helpful tips:</strong> When a PWD who usually takes bath refuses to do so, it may be due to being unwell. Hence, caregiver need to ask about their physical condition. During the bathing process: • talk to them gently and be careful not to hurt their pride. During the dressing process: • replace their clothes fasteners or buttons with Velcro tape • put signs on their clothes to distinguish the front and back • prepare their clothes in the correct order of putting on</td>
</tr>
<tr>
<td><strong>iii. Excretion:</strong></td>
<td>PWD may urinate in inappropriate places, repeatedly go to the bathroom or do not understand the need to urinate or defecate.</td>
<td><strong>Helpful tips:</strong> Caregiver may put a large sign on the bathroom door, keep the doorways bright and switch on the lights in the bathroom at night. Another tip is to bring the PWD to the toilet at frequent interval.</td>
</tr>
</tbody>
</table>

**Source:**
1. Division for Dementia and Community Care Promotion. Living together with people with dementia; Key points for the care of people with dementia at home. Kumamoto Prefecture; Department of Health and Social Services; 2013.
### USEFUL RESOURCES

<table>
<thead>
<tr>
<th>State</th>
<th>Organisation Information</th>
</tr>
</thead>
</table>
| **National** | ADFM National Dementia Caregivers Support Network  
Tel: ADFM HELPLINE at 03-79315850  
Facebook: Alzheimer’s Disease Foundation Malaysia - ADFM |
| **Penang** | Penang Dementia Association  
Tel: 016-6745429  
Facebook: Penang Dementia Association |
| **Perak** | Dementia Society Perak  
Ipoh AD Support Group  
Tel: 05-2411691 / 019-5712738  
Email: tdsperak@gmail.com  
Facebook: The Dementia Society Perak |
| **Selangor, Wilayah Persekutuan Kuala Lumpur & Putrajaya** | ADFM AD Support Group  
Tel: 03-79315850/016-6082513  
Email: jenny@adfm.org.my / jennyho8@gmail.com  
Facebook: Alzheimer’s Disease Foundation Malaysia - ADFM |
| **Negeri Sembilan** | Kumpulan Sokongan Dementia Negeri Sembilan (KUSDeNS)  
Email: wecaredementian9@gmail.com  
Tel: 06-7684804 |
| **Johor** | Johor Bahru Alzheimer’s Disease Support Association (JOBADA)  
Tel: 07-2222016 (JOBADA office)/012-7091277  
Email: jobadajohor@gmail.com  
Facebook: Jobada Johor |
| **Sabah** | Sabah Alzheimer’s Disease Association (Sabah AZ)  
Tel: 088-231030 / 088-270730  
Email: kjchau88@hotmail.com  
Facebook: Sabah Alzheimer's Disease Support Association |
| **Sarawak** | Trinity ElderCare Centre (TEC)  
Tel/Fax: 082-255758  
Email: tmceldercare@gmail.com  
Facebook: Trinity ElderCare Centre |
**ADVANCE CARE PLANNING**

Advance care planning (ACP) is a process of discussing and recording PWD's wishes, values and preferences of future care together with their family members and healthcare providers (HCP) which will take effect once the PWD lose their capacity to make decision.

<table>
<thead>
<tr>
<th>The discussion of ACP should include:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• benefits of planning ahead</td>
</tr>
<tr>
<td>• PWD’s proxy or substitute decision-maker when the PWD lacks capacity to make decisions</td>
</tr>
<tr>
<td>• advance statement about their wishes, values, preferences and beliefs regarding their future care</td>
</tr>
<tr>
<td>• advance decisions to refuse certain treatments e.g. intubation, cardiopulmonary resuscitation, enteral feeding, etc.</td>
</tr>
<tr>
<td>• their preferences for place of care and place of death</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendations for HCP during ACP discussion.</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Start ACP as early as possible when the PWD and family members are ready.</td>
</tr>
<tr>
<td>• ACP conversations are not one-off occurrence and it should be revised from time to time especially when changes of clinical condition occur.</td>
</tr>
<tr>
<td>• Try to understand the PWD from their perspectives before initiation of discussion on ACP - explore their life stories, important values, norms, beliefs and preferences,</td>
</tr>
<tr>
<td>• Use the language which is familiar to the PWD,</td>
</tr>
<tr>
<td>• Adjust conversation style and content to the PWD’s level and rhythm.</td>
</tr>
<tr>
<td>• Obtain the PWD’s permit to invite family members to join the conversation.</td>
</tr>
<tr>
<td>• Evaluate their disease awareness and inform them about the expected disease trajectory and possible end-of-life decisions.</td>
</tr>
<tr>
<td>• Explore the PWD’s current experiences, their fears and concerns for the future and end-of-life.</td>
</tr>
<tr>
<td>• Lead the conversation but do not force it or dominate the discussion.</td>
</tr>
<tr>
<td>• Keep connected with the PWD to ensure their maximum participation, respond to their emotions, attend to non-verbal communication and observe their behaviour.</td>
</tr>
</tbody>
</table>

**Source:**
## LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>^{11}C-PIB-PET</td>
<td>11C-labeled Pittsburgh compound B-positron emission tomography</td>
</tr>
<tr>
<td>^{123}I-FP-CIT</td>
<td>Iodine 123-radiolabeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane</td>
</tr>
<tr>
<td>^{123}I-MIBG</td>
<td>123I-metaiodobenzylguanidine</td>
</tr>
<tr>
<td>ACB</td>
<td>anticholinergic burden</td>
</tr>
<tr>
<td>ACE-III</td>
<td>Addenbrooke's Cognitive Examination-III</td>
</tr>
<tr>
<td>AChEI</td>
<td>acetylcholinesterase inhibitors</td>
</tr>
<tr>
<td>ACP</td>
<td>advance care planning</td>
</tr>
<tr>
<td>AD</td>
<td>Alzheimer's disease</td>
</tr>
<tr>
<td>AD-8</td>
<td>Eight-item Interview to Differentiate Aging and Dementia</td>
</tr>
<tr>
<td>ADAS-Cog</td>
<td>Alzheimer's Disease Assessment Scale-Cognitive Subscale</td>
</tr>
<tr>
<td>ADCS-CGIC</td>
<td>Alzheimer's Disease Cooperative Study – Clinical Global Impression of Change</td>
</tr>
<tr>
<td>ADDTC</td>
<td>Alzheimer's Disease Diagnostic and Treatment Centres</td>
</tr>
<tr>
<td>ADL</td>
<td>activity of daily living</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>AGREE II</td>
<td>Appraisal of Guidelines, Research and Evaluation II</td>
</tr>
<tr>
<td>aHR</td>
<td>adjusted hazard ratio</td>
</tr>
<tr>
<td>AMTS</td>
<td>Abbreviated Mental Test Score</td>
</tr>
<tr>
<td>ANI</td>
<td>Asymptomatic Neurocognitive Impairment</td>
</tr>
<tr>
<td>AP</td>
<td>antipsychotic</td>
</tr>
<tr>
<td>APOE4</td>
<td>apolipoprotein E4</td>
</tr>
<tr>
<td>ARB</td>
<td>angiotensin II receptor blockers</td>
</tr>
<tr>
<td>ARD</td>
<td>alcohol-related dementia</td>
</tr>
<tr>
<td>ART</td>
<td>antiretroviral therapy</td>
</tr>
<tr>
<td>BEHAVE-AD</td>
<td>Behavioural Pathology in Alzheimer’s Disease Rating Scale</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>BPRS</td>
<td>Brief Psychiatric Rating Scale</td>
</tr>
<tr>
<td>BPSD</td>
<td>behavioural and psychological symptoms of dementia</td>
</tr>
<tr>
<td>bvFTD</td>
<td>behavioural variant of frontotemporal dementia</td>
</tr>
<tr>
<td>CBT</td>
<td>cognitive behavioural therapy</td>
</tr>
<tr>
<td>CGI</td>
<td>Clinical Global Impression</td>
</tr>
<tr>
<td>CGI-C</td>
<td>CGI-Corrections</td>
</tr>
<tr>
<td>CGI-I</td>
<td>CGI-Improvement</td>
</tr>
<tr>
<td>CGI-S</td>
<td>CGI-Severity</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CIIBIC+</td>
<td>Clinician’s Interview-Based Impression of Change</td>
</tr>
<tr>
<td>CIND</td>
<td>cognitive impairment no dementia</td>
</tr>
<tr>
<td>CIND-PD</td>
<td>cognitive impairment in Parkinson’s Disease</td>
</tr>
<tr>
<td>cm^2</td>
<td>centimetre square</td>
</tr>
<tr>
<td>CMAI</td>
<td>Cohen-Mansfield Agitation Inventory</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CPE</td>
<td>CNS penetration effectiveness</td>
</tr>
<tr>
<td>CPG</td>
<td>clinical practice guidelines</td>
</tr>
<tr>
<td>CQ</td>
<td>clinical question</td>
</tr>
<tr>
<td>CrCl</td>
<td>creatinine clearance</td>
</tr>
<tr>
<td>CSDD</td>
<td>Cornell Scale for Depression in Dementia</td>
</tr>
<tr>
<td>CSF</td>
<td>cerebrospinal fluid</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>DAD</td>
<td>Disability Assessment for Dementia</td>
</tr>
<tr>
<td>DAT</td>
<td>dopamine transporter</td>
</tr>
<tr>
<td>DG</td>
<td>development group</td>
</tr>
<tr>
<td>DLB</td>
<td>dementia with Lewy Body</td>
</tr>
<tr>
<td>DM</td>
<td>diabetes mellitus</td>
</tr>
<tr>
<td>DSM-5</td>
<td>Diagnostic and Statistical Manual of Mental Disorders 5th Edition</td>
</tr>
<tr>
<td>EEG</td>
<td>electroencephalogram</td>
</tr>
<tr>
<td>ER</td>
<td>extended release</td>
</tr>
<tr>
<td>EGB761</td>
<td>ginkgo biloba extract 761</td>
</tr>
<tr>
<td>FAST</td>
<td>Functional Assessment Staging</td>
</tr>
<tr>
<td>FBI</td>
<td>Frontal Behavioural Inventory</td>
</tr>
<tr>
<td>FDG-PET</td>
<td>fluorodeoxyglucose-positron emission tomography</td>
</tr>
<tr>
<td>FTD</td>
<td>frontotemporal dementia</td>
</tr>
<tr>
<td>GDS</td>
<td>Global Deterioration Scale</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>GRADE</td>
<td>Grading of Recommendations, Assessment, Development and Evaluations</td>
</tr>
<tr>
<td>h</td>
<td>hour</td>
</tr>
<tr>
<td>HAD</td>
<td>HIV-associated Dementia</td>
</tr>
<tr>
<td>HANDs</td>
<td>HIV-associated Neurocognitive Disorders</td>
</tr>
<tr>
<td>HCP</td>
<td>healthcare providers</td>
</tr>
<tr>
<td>HDS</td>
<td>HIV Dementia Scale</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>HR</td>
<td>hazard ratio</td>
</tr>
<tr>
<td>HTA</td>
<td>health technology assessment</td>
</tr>
<tr>
<td>IADL</td>
<td>Instrumental Activity of Daily Living</td>
</tr>
<tr>
<td>ICD-10</td>
<td>International Classification of Diseases, Tenth Revision</td>
</tr>
<tr>
<td>IHDS</td>
<td>International HIV Dementia Scale</td>
</tr>
<tr>
<td>IM</td>
<td>intramuscular</td>
</tr>
<tr>
<td>IQCODE</td>
<td>Informant Questionnaire on Cognitive Decline in the Elderly</td>
</tr>
<tr>
<td>IR</td>
<td>immediate release</td>
</tr>
<tr>
<td>MADRS</td>
<td>Montgomery-Asberg Depression Rating Scale</td>
</tr>
<tr>
<td>MCI</td>
<td>mild cognitive impairment</td>
</tr>
<tr>
<td>MD</td>
<td>mean difference</td>
</tr>
<tr>
<td>MDS</td>
<td>Movement Disorder Society</td>
</tr>
<tr>
<td>mg</td>
<td>milligramme</td>
</tr>
<tr>
<td>MMSE</td>
<td>Mini Mental State Examination</td>
</tr>
<tr>
<td>MND</td>
<td>Mild Neurocognitive Disorder</td>
</tr>
<tr>
<td>MoCA</td>
<td>Montreal Cognitive Assessment</td>
</tr>
<tr>
<td>MoH</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>NBRs-A</td>
<td>Neurobehavioral Rating Scale-Agitation</td>
</tr>
<tr>
<td>NCDs</td>
<td>non-communicable diseases</td>
</tr>
<tr>
<td>NGOs</td>
<td>non-governmental organisations</td>
</tr>
<tr>
<td>NIA-AA</td>
<td>National Institute on Aging and Alzheimer's Association</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Care Excellence</td>
</tr>
<tr>
<td>NINDS-AIREN</td>
<td>National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences</td>
</tr>
<tr>
<td>NMDA</td>
<td>N-methyl-D-aspartate</td>
</tr>
<tr>
<td>NOSGER</td>
<td>Nurses’ Observation Scale for Geriatric Patients</td>
</tr>
<tr>
<td>NPI</td>
<td>Neuropsychiatric Inventory</td>
</tr>
<tr>
<td>NPI-A</td>
<td>Neuropsychiatric Inventory-agitation</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>NPZ3</td>
<td>neuropsychological z-score 3</td>
</tr>
<tr>
<td>NRT</td>
<td>nicotine replacement therapy</td>
</tr>
<tr>
<td>OR</td>
<td>odds ratio</td>
</tr>
<tr>
<td>p</td>
<td>P value</td>
</tr>
<tr>
<td>PIP</td>
<td>potentially inappropriate prescription</td>
</tr>
<tr>
<td>PDD</td>
<td>Parkinson’s Disease Dementia</td>
</tr>
<tr>
<td>PWD</td>
<td>people with dementia</td>
</tr>
<tr>
<td>QoL</td>
<td>quality of life</td>
</tr>
<tr>
<td>RC</td>
<td>review committee</td>
</tr>
<tr>
<td>RCT</td>
<td>randomised controlled trial</td>
</tr>
<tr>
<td>RR</td>
<td>relative risk</td>
</tr>
<tr>
<td>RT</td>
<td>reminiscence therapy</td>
</tr>
<tr>
<td>SIB</td>
<td>Severe Impairment Battery</td>
</tr>
<tr>
<td>SLUMS</td>
<td>Saint Louis University Mental Status</td>
</tr>
<tr>
<td>SMD</td>
<td>standardised mean difference</td>
</tr>
<tr>
<td>SPECT</td>
<td>single-photon emission CT</td>
</tr>
<tr>
<td>SUCRA</td>
<td>surface under cumulative ranking</td>
</tr>
<tr>
<td>TBI</td>
<td>traumatic brain injury</td>
</tr>
<tr>
<td>TC</td>
<td>total serum cholesterol</td>
</tr>
<tr>
<td>TCM</td>
<td>traditional and complementary medicine</td>
</tr>
<tr>
<td>TEAEs</td>
<td>treatment-emergent adverse events/effects</td>
</tr>
<tr>
<td>US FDA</td>
<td>United States Food and Drug Administration</td>
</tr>
<tr>
<td>VaD</td>
<td>vascular dementia</td>
</tr>
<tr>
<td>V-ADAS-cog</td>
<td>Vascular Dementia Assessment Scale Cognitive Subscale</td>
</tr>
<tr>
<td>VCAT</td>
<td>Visual Cognitive Assessment Test</td>
</tr>
<tr>
<td>VDRL</td>
<td>Venereal Disease Research Laboratory test</td>
</tr>
<tr>
<td>vs</td>
<td>versus</td>
</tr>
<tr>
<td>WAB</td>
<td>Western Aphasia Battery</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WMD</td>
<td>weighted mean difference</td>
</tr>
<tr>
<td>ZBI</td>
<td>Zarit Burden Interview</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENT

The CPG DG members would like to express their gratitude and appreciation to the following for their contributions:

- Panel of external reviewers who reviewed the draft
- Technical Advisory Committee of CPG for their valuable input and feedback
- Health Technology Assessment and Clinical Practice Guidelines Council for approving the CPG
- Dr Toh Chin Lee, Senior Consultant Child and Adolescent Psychiatrist on the development of the CPG
- Dr Junainah Sabirin, Consultant Public Health Physician on the development of the CPG
- Mr. Mohd Tholib Ibrahim and Ms. Norharlina Che Zakaria on retrieval of evidence
- Alzheimer’s Disease Foundation Malaysia on support and materials for the CPG
- All those who have contributed directly or indirectly to the development of the CPG

DISCLOSURE STATEMENT

The panel members of both DG and RC had completed disclosure forms. None held shares in pharmaceutical firms or acts as consultants to such firms. Details are available upon request from the CPG Secretariat.

SOURCE OF FUNDING

The development of the CPG on Management of Dementia (Third Edition) was supported financially in its entirety by the MoH Malaysia.